{"timestamp": "2026-02-11T13:17:29.343539+00:00", "event_type": "run_start", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "graph_dir": "experiments/KAG/results/sprint4_pet_20260210T152550Z", "model": "anthropic/claude-sonnet-4-5-20250929", "sub_model": "anthropic/claude-haiku-4-5-20251001", "max_iters": 25, "max_calls": 60, "doc_stats": {"triples": 1133, "types": {"doco:Document": 1, "doco:Title": 1, "doco:Figure": 10, "doco:Paragraph": 86, "doco:SectionTitle": 18, "deo:Caption": 12, "doco:Table": 3, "deo:BibliographicReference": 37, "doco:Section": 18, "deo:Discussion": 1, "deo:Conclusion": 1, "deo:Acknowledgements": 1, "doco:ListOfReferences": 1, "deo:Introduction": 1, "deo:Methods": 1}}}}
{"timestamp": "2026-02-11T13:17:29.348307+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "phase": "rlm_start", "context_length": 3709, "task_length": 3335}}
{"timestamp": "2026-02-11T13:17:39.318139+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_section_content", "args": ["ex:section_2"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:17:39.319380+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_section_content", "error": null, "result_size": 375, "result_preview": "[{'iri': 'ex:b_p001_0009', 'types': ['doco:Paragraph'], 'text_preview': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca', 'page': 1, '_section_title': '## A B S T R A C T'}, {'iri': 'ex:b_p001_0010', 'types': ['doco:Paragraph'], 'text_preview': '\u00a9 2017 Elsevier Ltd. All rights reserved.', 'page': 1}]"}}
{"timestamp": "2026-02-11T13:17:49.005151+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p001_0009"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:17:49.005906+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 895, "result_preview": "{'iri': 'ex:b_p001_0009', 'properties': {'rdf:type': 'doco:Paragraph', 'kag:fullText': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify cancer cells and stimulate immune responses. The Programmed Death-1 (PD-1) protein is an immunoinhibitory receptor expressed by activated cytotoxic T-lymphocytes (CTL) that seek out and destroy cancer cells. Multiple cancer types express and upregulate the Programmed Death-Ligand 1 (PD-L1) and 2 (PD-L2) which bind to PD-1 as an immune escape mechanism. Nivolumab is a fully human ...<truncated>', 'kag:hasBBox': '[[347, 408, 944, 640]]', 'kag:hasContentRef': 'paragraph:20c93acd25b25b62', 'kag:mainText': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca', 'kag:pageNumber': '1', '_contained_by': ['ex:section_2']}}"}}
{"timestamp": "2026-02-11T13:17:49.006560+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["Nivolumab", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:17:49.010336+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1712, "result_preview": "[{'iri': 'ex:b_p001_0001', 'types': ['doco:Title'], 'page': 1, 'score': 1, 'snippet': '...and preclinical PET evaluation of  \\\\( ^{89} \\\\) Zr-nivolumab (BMS-936558) in healthy non-human primates', 'text_preview': '# Radiosynthesis and preclinical PET evaluation of  \\\\( ^{89} \\\\) Zr-nivolumab (BMS-936558) in healthy non-human primates'}, {'iri': 'ex:b_p001_0007', 'types': ['doco:Paragraph'], 'page': 1, 'score': 1, 'snippet': 'Keywords:\\nNivolumab\\nOpdivo\\nPET\\nZirconium-89\\nPD-1\\nPD-L1\\nBMS-936558', 'text_preview': 'Keywords: Nivolumab Opdivo PET Zirconium-89 PD-1 PD-L1 BMS-936558'}, {'iri': 'ex:b_p001_0009', 'types': ['doco:Paragraph'], 'page': 1, 'score': 1, 'snippet': '...which bind to PD-1 as an immune escape mechanism. Nivolumab is a fully human IgG4 anti-PD-1 monoclonal antibody (mAb) approved for treatment of multip...', 'text_preview': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca'}, {'iri': 'ex:b_p002_0002', 'types': ['doco:Paragraph'], 'page': 2, 'score': 1, 'snippet': 'Nivolumab is a fully human IgG4 anti-PD-1 mAb also known as Opdivo, BMS-936558, MDX-1106, and ONO-45...', 'text_preview': 'Nivolum...<truncated>"}}
{"timestamp": "2026-02-11T13:17:49.010930+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["DFO", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:17:49.012468+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1626, "result_preview": "[{'iri': 'ex:b_p002_0004', 'types': ['doco:Paragraph'], 'page': 2, 'score': 1, 'snippet': 'Desferrioxamine (DFO) is the most common chelator for  \\\\( {}^{89} \\\\) Zr-labeling, available commercially as  \\\\( {}^{8...', 'text_preview': 'Desferrioxamine (DFO) is the most common chelator for  \\\\( {}^{89} \\\\) Zr-labeling, available commercially as  \\\\( {}^{89} '}, {'iri': 'ex:b_p002_0007', 'types': ['doco:SectionTitle'], 'page': 2, 'score': 1, 'snippet': '## 2.1. Nivolumab conjugation with DFO', 'text_preview': '## 2.1. Nivolumab conjugation with DFO'}, {'iri': 'ex:b_p002_0008', 'types': ['doco:Paragraph'], 'page': 2, 'score': 1, 'snippet': '...rmation of a thiourea linkage to the bifunctional DFO chelator derivative, 1-(4-isothiocyanatophenyl)-3-[6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acet...', 'text_preview': 'Nivolumab was modified by formation of a thiourea linkage to the bifunctional DFO chelator derivative, 1-(4-isothiocyana'}, {'iri': 'ex:b_p002_0009', 'types': ['doco:Paragraph'], 'page': 2, 'score': 1, 'snippet': '...\\\\( _{3} \\\\) , pH 9.0. A 20-fold excess of p-SCN-Bn-DFO in 1 mL DMSO was added to the mAb (10 mg in 9 mL) and incubated for 3 h at room temperature. Pre...', 'text...<truncated>"}}
{"timestamp": "2026-02-11T13:17:49.012955+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["89Zr", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:17:49.013355+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 2, "result_preview": "[]"}}
{"timestamp": "2026-02-11T13:17:58.941308+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["Zirconium", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:17:58.943102+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1819, "result_preview": "[{'iri': 'ex:b_p001_0007', 'types': ['doco:Paragraph'], 'page': 1, 'score': 1, 'snippet': 'Keywords:\\nNivolumab\\nOpdivo\\nPET\\nZirconium-89\\nPD-1\\nPD-L1\\nBMS-936558', 'text_preview': 'Keywords: Nivolumab Opdivo PET Zirconium-89 PD-1 PD-L1 BMS-936558'}, {'iri': 'ex:b_p008_0028', 'types': ['deo:BibliographicReference', 'doco:Paragraph'], 'page': 8, 'score': 1, 'snippet': '...iometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858\u20132902.', 'text_preview': '16. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zircon'}, {'iri': 'ex:b_p008_0030', 'types': ['deo:BibliographicReference', 'doco:Paragraph'], 'page': 8, 'score': 1, 'snippet': '18. Zhang Y, Hong H, Cai W. PET tracers based on zirconium-89. Curr Radiopharm. 2011;4:131\u2013139.', 'text_preview': '18. Zhang Y, Hong H, Cai W. PET tracers based on zirconium-89. Curr Radiopharm. 2011;4:131\u2013139.'}, {'iri': 'ex:b_p008_0040', 'types': ['deo:BibliographicReference', 'doco:Paragraph'], 'page': 8, 'score': 1, 'snippet': '...n and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifuncti...<truncated>"}}
{"timestamp": "2026-02-11T13:17:58.944183+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_section_content", "args": ["ex:section_5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:17:58.944812+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_section_content", "error": null, "result_size": 1097, "result_preview": "[{'iri': 'ex:b_p002_0008', 'types': ['doco:Paragraph'], 'text_preview': 'Nivolumab was modified by formation of a thiourea linkage to the bifunctional DFO chelator derivative, 1-(4-isothiocyana', 'page': 2, '_section_title': '## 2.1. Nivolumab conjugation with DFO'}, {'iri': 'ex:b_p002_0009', 'types': ['doco:Paragraph'], 'text_preview': 'Nivolumab (10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentaacetic acid (DTPA) and polysorb', 'page': 2}, {'iri': 'ex:b_p002_0010', 'types': ['doco:Paragraph'], 'text_preview': 'The purity was determined by analytical SEC (10/300 GL Superdex 200, PBS buffer mobile phase) and protein concentration ', 'page': 2}, {'iri': 'ex:b_p002_0011', 'types': ['doco:Paragraph'], 'text_preview': 'SPR experiments were performed to calculate the  \\\\( K_{D} \\\\)  for human PD-1 (hPD1(25\u2013167)-Myc-TVMV-His, Bristol-Myers S', 'page': 2}, {'iri': 'ex:b_p002_0012', 'types': ['doco:Paragraph'], 'text_preview': 'Response levels obtained for the primary mAb were approximately 3000 RU. Nivolumab and nivolumab-DFO were captured on th', 'page': 2}]"}}
{"timestamp": "2026-02-11T13:17:58.946252+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_section_content", "args": ["ex:section_6"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:17:58.946792+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_section_content", "error": null, "result_size": 1035, "result_preview": "[{'iri': 'ex:b_p002_0014', 'types': ['doco:Paragraph'], 'text_preview': '\\\\( ^{89} \\\\) Zr-oxalic acid was produced via the  \\\\( {}^{89} \\\\) Y(p,n) \\\\( ^{89} \\\\) Zr transmutation reaction on a cyclotr', 'page': 2, '_section_title': '## 2.2. Radiolabeling and quality control of  \\\\( ^{89} \\\\) Zr-nivolumab'}, {'iri': 'ex:b_p003_0001', 'types': ['doco:Figure'], 'text_preview': '[image] page=3 bbox=[[90, 81, 470, 872]]', 'page': 3}, {'iri': 'ex:b_p003_0002', 'types': ['deo:Caption'], 'text_preview': 'Scheme 1. Nivolumab conjugation to p-SCN-Bn-DFO and radiolabeling with  \\\\( ^{89} \\\\) Zr \\\\( ^{4+} \\\\) .', 'page': 3}, {'iri': 'ex:b_p003_0003', 'types': ['doco:Paragraph'], 'text_preview': 'prepared from  \\\\( {}^{89} \\\\) Zr-oxalate and nivolumab-DFO following the procedures reported by Vosjan and co-workers wit', 'page': 3}, {'iri': 'ex:b_p003_0004', 'types': ['doco:Paragraph'], 'text_preview': 'The reaction was transferred to a PD-10 column (GE Healthcare) previously equilibrated with PBS buffer prior to loading ', 'page': 3}]"}}
{"timestamp": "2026-02-11T13:18:10.441923+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p002_0008"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:10.442671+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 674, "result_preview": "{'iri': 'ex:b_p002_0008', 'properties': {'rdf:type': 'doco:Paragraph', 'kag:fullText': 'Nivolumab was modified by formation of a thiourea linkage to the bifunctional DFO chelator derivative, 1-(4-isothiocyanatophenyl)-3-[6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaecisoanet]thiourea (p-SCN-Bn-DFO, Scheme. 1, step 1, Macrocyclics, B-705).', 'kag:hasBBox': '[[499, 220, 931, 287]]', 'kag:hasContentRef': 'paragraph:1bcac25ae8e92dd8', 'kag:mainText': 'Nivolumab was modified by formation of a thiourea linkage to the bifunctional DFO chelator derivative, 1-(4-isothiocyana', 'kag:pageNumber': '2', '_contained_by': ['ex:section_5']}}"}}
{"timestamp": "2026-02-11T13:18:10.443327+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p002_0010"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:10.443747+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 667, "result_preview": "{'iri': 'ex:b_p002_0010', 'properties': {'rdf:type': 'doco:Paragraph', 'kag:fullText': 'The purity was determined by analytical SEC (10/300 GL Superdex 200, PBS buffer mobile phase) and protein concentration by NanoDrop 2000c spectrophotometer. A CAR was calculated from the relative peak intensities in the deconvoluted LC/MS spectra of intact and/or reduced nivolumab-DFO.', 'kag:hasBBox': '[[499, 419, 931, 485]]', 'kag:hasContentRef': 'paragraph:10ae1f272f84a086', 'kag:mainText': 'The purity was determined by analytical SEC (10/300 GL Superdex 200, PBS buffer mobile phase) and protein concentration ', 'kag:pageNumber': '2', '_contained_by': ['ex:section_5']}}"}}
{"timestamp": "2026-02-11T13:18:10.444296+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p003_0003"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:10.444761+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 936, "result_preview": "{'iri': 'ex:b_p003_0003', 'properties': {'rdf:type': 'doco:Paragraph', 'kag:fullText': 'prepared from  \\\\( {}^{89} \\\\) Zr-oxalate and nivolumab-DFO following the procedures reported by Vosjan and co-workers with minor modifications (Scheme. 1, step 2). \\\\( ^{28} \\\\)  An average of 15 mCi of  \\\\( {}^{89} \\\\) Zr-oxalic acid in 300  \\\\( \\\\mu \\\\) L was neutralized with 300  \\\\( \\\\mu \\\\) L of 2 M Na \\\\( _{2} \\\\) CO \\\\( _{3} \\\\) . The volume was then diluted with 0.5 mL of 0.5 M HEPES buffer (pH 7.2). To this solution, nivolumab-DFO was added (0.5 mL of 1.5 mg/mL, 750  \\\\( \\\\mu \\\\) g) then an additional 0....<truncated>', 'kag:hasBBox': '[[65, 910, 494, 951], [515, 82, 946, 174]]', 'kag:hasContentRef': 'paragraph:3ce4538bea15a58b', 'kag:mainText': 'prepared from  \\\\( {}^{89} \\\\) Zr-oxalate and nivolumab-DFO following the procedures reported by Vosjan and co-workers wit', 'kag:pageNumber': '3', '_contained_by': ['ex:section_6']}}"}}
{"timestamp": "2026-02-11T13:18:10.445134+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["yield", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:10.445981+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1381, "result_preview": "[{'iri': 'ex:b_p004_0011', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '...olumab-DFO was isolated after purification with a yield of 88% (8.8 mg, 0.44 mg/mL in PBS) from the parent mAb (10 mg). Purity was determined to be  \\\\...', 'text_preview': 'Preparation of nivolumab-DFO in Scheme 1, step 1, was achieved through thiourea bond formation between the p-SCN-Bn-DFO '}, {'iri': 'ex:b_p004_0014', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '\\\\( ^{89} \\\\) Zr-labeling yielded 225\u2013341 MBq of  \\\\( ^{89} \\\\) Zr-nivolumab with a moderate radiochemical yield of  \\\\( 53 \\\\pm 8...', 'text_preview': '\\\\( ^{89} \\\\) Zr-labeling yielded 225\u2013341 MBq of  \\\\( ^{89} \\\\) Zr-nivolumab with a moderate radiochemical yield of  \\\\( 53 \\\\'}, {'iri': 'ex:b_p004_0018', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '\\\\( ^{b} \\\\)  Radiochemical yield, non-decay corrected.', 'text_preview': '\\\\( ^{b} \\\\)  Radiochemical yield, non-decay corrected.'}, {'iri': 'ex:b_p008_0005', 'types': ['doco:Paragraph'], 'page': 8, 'score': 1, 'snippet': '... {}^{89} \\\\) Zr with good purity and radiochemical yield. The in vivo NIHP imaging with tracer only  \\\\( {}^{89} \\\\) Z...<truncated>"}}
{"timestamp": "2026-02-11T13:18:22.179701+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["CAR", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:22.182152+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1910, "result_preview": "[{'iri': 'ex:b_p001_0012', 'types': ['doco:Paragraph'], 'page': 1, 'score': 1, 'snippet': 'The standard of care for many cancers includes combinations of chemotherapy, radiation, and surgical resection when ...', 'text_preview': 'The standard of care for many cancers includes combinations of chemotherapy, radiation, and surgical resection when poss'}, {'iri': 'ex:b_p002_0004', 'types': ['doco:Paragraph'], 'page': 2, 'score': 1, 'snippet': '...ant to determine the conjugate to antibody ratio (CAR) to minimize loss of biological activity from over modification. Site-specific DFO labeling of m...', 'text_preview': 'Desferrioxamine (DFO) is the most common chelator for  \\\\( {}^{89} \\\\) Zr-labeling, available commercially as  \\\\( {}^{89} '}, {'iri': 'ex:b_p002_0009', 'types': ['doco:Paragraph'], 'page': 2, 'score': 1, 'snippet': '...sing a HiLoad 26/60 Superdex 200 column (GE Healthcare) and PBS buffer (150 mM NaCl, 200 mM NaPO \\\\( _{4} \\\\) , pH 7.2, Sigma-Aldrich) as eluent.', 'text_preview': 'Nivolumab (10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentaacetic acid (DTPA) and polysorb'}, {'iri': 'ex:b_p002_0010', 'types': ['doco:Paragraph'], 'page': 2, 'scor...<truncated>"}}
{"timestamp": "2026-02-11T13:18:22.182840+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["specific activity", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:22.184446+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1960, "result_preview": "[{'iri': 'ex:b_p001_0009', 'types': ['doco:Paragraph'], 'page': 1, 'score': 2, 'snippet': '...tified by region of interest (ROI) analysis. Radioactivity in the spleen was significantly reduced by addition of excess nivolumab compared to the tra...', 'text_preview': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca'}, {'iri': 'ex:b_p002_0004', 'types': ['doco:Paragraph'], 'page': 2, 'score': 2, 'snippet': '...tibody ratio (CAR) to minimize loss of biological activity from over modification. Site-specific DFO labeling of mAbs has been examined using thiol re...', 'text_preview': 'Desferrioxamine (DFO) is the most common chelator for  \\\\( {}^{89} \\\\) Zr-labeling, available commercially as  \\\\( {}^{89} '}, {'iri': 'ex:b_p003_0004', 'types': ['doco:Paragraph'], 'page': 3, 'score': 2, 'snippet': '...ly the first 1 mL fraction contained minimal radioactivity followed by a 1.5 mL fraction with the majority of purified  \\\\( {}^{89} \\\\) Zr-nivolumab tha...', 'text_preview': 'The reaction was transferred to a PD-10 column (GE Healthcare) previously equilibrated with PBS buffer prior to loading '}, {'iri': 'ex:b_p005_0010'...<truncated>"}}
{"timestamp": "2026-02-11T13:18:22.184889+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["KD", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:22.185515+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 391, "result_preview": "[{'iri': 'ex:b_p005_0009', 'types': ['deo:Caption'], 'page': 5, 'score': 1, 'snippet': '...ed with gel filtration standard. UV Region 1: 670 kDa (18 min), Region 2: 158 kDa (26 min), Region 3: 44 kDa (31 min), Region 4: 17 kDa (36 min), Regi...', 'text_preview': 'Fig. 1. SEC profiles of  \\\\( {}^{89} \\\\) Zr-nivolumab in radioactive counts and UV absorbance. a  \\\\( {}^{89} \\\\) Zr-nivolum'}]"}}
{"timestamp": "2026-02-11T13:18:22.185875+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["Results", "10"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:22.186573+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1347, "result_preview": "[{'iri': 'ex:b_p001_0009', 'types': ['doco:Paragraph'], 'page': 1, 'score': 1, 'snippet': '...sues: lung, muscle, brain, heart, and kidney. The results indicate specific biodistribution to the spleen, which can be blocked by co-administration o...', 'text_preview': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca'}, {'iri': 'ex:b_p004_0009', 'types': ['doco:SectionTitle'], 'page': 4, 'score': 1, 'snippet': '## 3. Results and discussion', 'text_preview': '## 3. Results and discussion'}, {'iri': 'ex:b_p005_0014', 'types': ['doco:Paragraph'], 'page': 5, 'score': 1, 'snippet': '...lthy NHPs. Despite a small number of animals, the results from this study show that splenic uptake of  \\\\( {}^{89} \\\\) Zr-nivolumab is markedly influenc...', 'text_preview': 'This is the first labeling of nivolumab with  \\\\( {}^{89} \\\\) Zr for imaging with co-registered PET/MRI imaging to evaluat'}, {'iri': 'ex:b_p005_0015', 'types': ['doco:Paragraph'], 'page': 5, 'score': 1, 'snippet': '...s and other lymphocytes, which is consistent with results published by Wang and co-workers in NHPs.\u00b9\u2079 Biodistribution of \u2078\u2079Zr-nivolumab in other tiss...<truncated>"}}
{"timestamp": "2026-02-11T13:18:34.671083+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_section_content", "args": ["ex:section_9"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:34.672049+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_section_content", "error": null, "result_size": 710, "result_preview": "[{'iri': 'ex:b_p004_0006', 'types': ['doco:Paragraph'], 'text_preview': 'PET images (axial field of view of 7.6 cm) were acquired and scanners calibrated for  \\\\( {}^{89} \\\\) Zr imaging. A 10 min', 'page': 4, '_section_title': '## 2.5. Positron emission tomography imaging and image analysis'}, {'iri': 'ex:b_p004_0007', 'types': ['doco:Paragraph'], 'text_preview': '54.5 \u00b1 11.0 MBq of  \\\\( {}^{89} \\\\) Zr-DFO-nivolumab was injected as a slow bolus over 20 min via cephalic vein in each NH', 'page': 4}, {'iri': 'ex:b_p004_0008', 'types': ['doco:Paragraph'], 'text_preview': 'MRI and PET images were manually co-registered using fiducial markers and anatomical information in software-co-registra', 'page': 4}]"}}
{"timestamp": "2026-02-11T13:18:34.672652+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p004_0011"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:34.673130+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 935, "result_preview": "{'iri': 'ex:b_p004_0011', 'properties': {'rdf:type': 'doco:Paragraph', 'kag:fullText': 'Preparation of nivolumab-DFO in Scheme 1, step 1, was achieved through thiourea bond formation between the p-SCN-Bn-DFO chelator and lysine on the mAb. Nivolumab-DFO was isolated after purification with a yield of 88% (8.8 mg, 0.44 mg/mL in PBS) from the parent mAb (10 mg). Purity was determined to be  \\\\( >95\\\\% \\\\)  with a CAR of 1.14 (Fig. S3). The chelate ratio was determined by LC-MS versus isotope dilution assay. \\\\( ^{30-32} \\\\)  Future synthesis should lower the excess of the p-SCN-Bn-DFO che...<truncated>', 'kag:hasBBox': '[[499, 234, 933, 392]]', 'kag:hasContentRef': 'paragraph:225981ae853fedff', 'kag:mainText': 'Preparation of nivolumab-DFO in Scheme 1, step 1, was achieved through thiourea bond formation between the p-SCN-Bn-DFO ', 'kag:pageNumber': '4', 'kag:refersTo': 'ex:b_p003_0001', '_contained_by': ['ex:section_11']}}"}}
{"timestamp": "2026-02-11T13:18:34.673627+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p004_0014"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:34.673981+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 913, "result_preview": "{'iri': 'ex:b_p004_0014', 'properties': {'rdf:type': 'doco:Paragraph', 'kag:fullText': '\\\\( ^{89} \\\\) Zr-labeling yielded 225\u2013341 MBq of  \\\\( ^{89} \\\\) Zr-nivolumab with a moderate radiochemical yield of  \\\\( 53 \\\\pm 8\\\\% \\\\)  (non-decay-corrected). Both yields were recorded from the fraction used for imaging to optimize purity, thus resulting in a lower observed yields than the reaction produced. Purification of the tracer was done with PBS which could have hindered the yield due to interaction of the chloride ions resulting in radiolysis or phosphate chelating free  \\\\( ^{89} \\\\) Zr. \\\\( ^{...<truncated>', 'kag:hasBBox': '[[499, 595, 934, 705]]', 'kag:hasContentRef': 'paragraph:90a123277e5a2f3e', 'kag:mainText': '\\\\( ^{89} \\\\) Zr-labeling yielded 225\u2013341 MBq of  \\\\( ^{89} \\\\) Zr-nivolumab with a moderate radiochemical yield of  \\\\( 53 \\\\', 'kag:pageNumber': '4', '_contained_by': ['ex:section_12']}}"}}
{"timestamp": "2026-02-11T13:18:34.674289+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["CAR of", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:34.681002+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1919, "result_preview": "[{'iri': 'ex:b_p001_0012', 'types': ['doco:Paragraph'], 'page': 1, 'score': 2, 'snippet': 'The standard of care for many cancers includes combinations of chemotherapy, radiation, and surgical resection wh...', 'text_preview': 'The standard of care for many cancers includes combinations of chemotherapy, radiation, and surgical resection when poss'}, {'iri': 'ex:b_p002_0004', 'types': ['doco:Paragraph'], 'page': 2, 'score': 2, 'snippet': '... widely used for in vivo imaging due to stability of the DFO- \\\\( Zr^{4+} \\\\)  complex, the commercial availability of DFO, and translational use in hum...', 'text_preview': 'Desferrioxamine (DFO) is the most common chelator for  \\\\( {}^{89} \\\\) Zr-labeling, available commercially as  \\\\( {}^{89} '}, {'iri': 'ex:b_p002_0009', 'types': ['doco:Paragraph'], 'page': 2, 'score': 2, 'snippet': '...0.1 M NaHCO \\\\( _{3} \\\\) , pH 9.0. A 20-fold excess of p-SCN-Bn-DFO in 1 mL DMSO was added to the mAb (10 mg in 9 mL) and incubated for 3 h at room temp...', 'text_preview': 'Nivolumab (10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentaacetic acid (DTPA) and polysorb'}, {'iri': 'ex:b_p002_0010', 'types': ['doco:Paragraph'], 'page':...<truncated>"}}
{"timestamp": "2026-02-11T13:18:45.015857+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["mCi", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:45.016983+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 402, "result_preview": "[{'iri': 'ex:b_p003_0003', 'types': ['doco:Paragraph'], 'page': 3, 'score': 1, 'snippet': '...Scheme. 1, step 2). \\\\( ^{28} \\\\)  An average of 15 mCi of  \\\\( {}^{89} \\\\) Zr-oxalic acid in 300  \\\\( \\\\mu \\\\) L was neutralized with 300  \\\\( \\\\mu \\\\) L of 2 ...', 'text_preview': 'prepared from  \\\\( {}^{89} \\\\) Zr-oxalate and nivolumab-DFO following the procedures reported by Vosjan and co-workers wit'}]"}}
{"timestamp": "2026-02-11T13:18:45.017520+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["MBq", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:45.018330+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1532, "result_preview": "[{'iri': 'ex:b_p004_0007', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '54.5 \u00b1 11.0 MBq of  \\\\( {}^{89} \\\\) Zr-DFO-nivolumab was injected as a slow bolus over 20 min via cephalic vein in...', 'text_preview': '54.5 \u00b1 11.0 MBq of  \\\\( {}^{89} \\\\) Zr-DFO-nivolumab was injected as a slow bolus over 20 min via cephalic vein in each NH'}, {'iri': 'ex:b_p004_0014', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '\\\\( ^{89} \\\\) Zr-labeling yielded 225\u2013341 MBq of  \\\\( ^{89} \\\\) Zr-nivolumab with a moderate radiochemical yield of  \\\\( 53 \\\\pm 8\\\\% \\\\)  (non-deca...', 'text_preview': '\\\\( ^{89} \\\\) Zr-labeling yielded 225\u2013341 MBq of  \\\\( ^{89} \\\\) Zr-nivolumab with a moderate radiochemical yield of  \\\\( 53 \\\\'}, {'iri': 'ex:b_p005_0010', 'types': ['doco:Paragraph'], 'page': 5, 'score': 1, 'snippet': '... activity was calculated to be  \\\\( 352 \\\\pm 87 \\\\)  MBq/mg, see Table 1 for individual reaction data. Analysis by SEC determined the samples had good pu...', 'text_preview': 'purification conditions in future studies to isolate more  \\\\( {}^{89} \\\\) Zr-nivolumab with 0.25 M sodium acetate buffer '}, {'iri': 'ex:b_p004_0016', 'types': ['doco:Table'], 'page': 4...<truncated>"}}
{"timestamp": "2026-02-11T13:18:45.018670+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p002_0011"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:45.019014+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 901, "result_preview": "{'iri': 'ex:b_p002_0011', 'properties': {'rdf:type': 'doco:Paragraph', 'kag:fullText': 'SPR experiments were performed to calculate the  \\\\( K_{D} \\\\)  for human PD-1 (hPD1(25\u2013167)-Myc-TVMV-His, Bristol-Myers Squibb) to nivolumab and nivolumab-DFO. \\\\( ^{27} \\\\)  Each study was done at 25 \u00b0C using a ProteOn XPR36 instrument with a running buffer of PBS with 0.05% Tween (TEKNOVA, P1192), that is held constant throughout the experiment. An anti-human IgG mAb was directly immobilized via amine coupling on a GLC sensor chip. The chip surface was then activated with a 1:1 mixture of 40 mM N...<truncated>', 'kag:hasBBox': '[[499, 484, 932, 696]]', 'kag:hasContentRef': 'paragraph:fa780c316fa6cec7', 'kag:mainText': 'SPR experiments were performed to calculate the  \\\\( K_{D} \\\\)  for human PD-1 (hPD1(25\u2013167)-Myc-TVMV-His, Bristol-Myers S', 'kag:pageNumber': '2', '_contained_by': ['ex:section_5']}}"}}
{"timestamp": "2026-02-11T13:18:45.019297+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p002_0012"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:45.019712+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 903, "result_preview": "{'iri': 'ex:b_p002_0012', 'properties': {'rdf:type': 'doco:Paragraph', 'kag:fullText': 'Response levels obtained for the primary mAb were approximately 3000 RU. Nivolumab and nivolumab-DFO were captured on the surface by the anti-human IgG to a response level of approximately 550 RU. Five concentrations of hPD-1 (from 40 nM to 2.5 nM, with a 2-fold serial dilution in the running buffer) were injected at 30  \\\\( \\\\mu \\\\) L/min for 3 min and the dissociation was monitored for 10 min. Surfaces were regenerated with two injections of 0.85%  \\\\( H_{3}PO_{4} \\\\)  (100  \\\\( \\\\mu \\\\) L/min for 18 ...<truncated>', 'kag:hasBBox': '[[498, 696, 932, 854]]', 'kag:hasContentRef': 'paragraph:cb8fe303f90c22f5', 'kag:mainText': 'Response levels obtained for the primary mAb were approximately 3000 RU. Nivolumab and nivolumab-DFO were captured on th', 'kag:pageNumber': '2', '_contained_by': ['ex:section_5']}}"}}
{"timestamp": "2026-02-11T13:18:56.953319+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["nM", "10"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:56.954296+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1179, "result_preview": "[{'iri': 'ex:b_p002_0012', 'types': ['doco:Paragraph'], 'page': 2, 'score': 1, 'snippet': '...ely 550 RU. Five concentrations of hPD-1 (from 40 nM to 2.5 nM, with a 2-fold serial dilution in the running buffer) were injected at 30  \\\\( \\\\mu \\\\) L/...', 'text_preview': 'Response levels obtained for the primary mAb were approximately 3000 RU. Nivolumab and nivolumab-DFO were captured on th'}, {'iri': 'ex:b_p003_0007', 'types': ['doco:Paragraph'], 'page': 3, 'score': 1, 'snippet': '...em transfer and to provide precise anatomical alignment. If necessary, ventilator tidal volume was utilized at 10\u201320 mL/kg for the procedure to mainta...', 'text_preview': 'PET images were acquired (microPET F220 scanner (Siemens Preclinical Solutions, Knoxville, TN)) were acquired and co-reg'}, {'iri': 'ex:b_p004_0012', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '...to hPD-1 are similar with a  \\\\( K_{D} \\\\)  of 3.10 nM for nivolumab and 3.75 nM for nivolumab-DFO (Fig. S4). These are comparable to binding of nivolum...', 'text_preview': 'The  \\\\( K_{D} \\\\)  values for nivolumab and nivolumab-DFO binding to hPD-1 are similar with a  \\\\( K_{D} \\\\)  of 3.10 nM fo'}]"}}
{"timestamp": "2026-02-11T13:18:56.954854+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["biodistribution", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:56.955832+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1958, "result_preview": "[{'iri': 'ex:b_p001_0009', 'types': ['doco:Paragraph'], 'page': 1, 'score': 1, 'snippet': '...on-human primates (NHP) as a preliminary study of biodistribution and clearance. The radiochemical and in vivo stabilities of the  \\\\( ^{89} \\\\) Zr comp...', 'text_preview': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca'}, {'iri': 'ex:b_p002_0003', 'types': ['doco:Paragraph'], 'page': 2, 'score': 1, 'snippet': '...use pharmacokinetics can require days for optimal biodistribution. \\\\( ^{17,18} \\\\)  Given that nivolumab has a dose-dependent half-life of 5 (1 mg/kg) ...', 'text_preview': 'In recent years, a number of radioisotopes have been employed for antibody-based positron emission tomography (PET) and '}, {'iri': 'ex:b_p004_0008', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '...Data Examiner (AMIDE). \\\\( ^{29} \\\\)  Image-derived biodistribution over the course of the imaging study (up to 8 days post injection, p.i.) were measur...', 'text_preview': 'MRI and PET images were manually co-registered using fiducial markers and anatomical information in software-co-registra'}, {'iri': 'ex:b_p005_0014...<truncated>"}}
{"timestamp": "2026-02-11T13:18:56.956204+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["uptake", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:56.957266+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1931, "result_preview": "[{'iri': 'ex:b_p001_0009', 'types': ['doco:Paragraph'], 'page': 1, 'score': 1, 'snippet': '...s following injection. Image-derived standardized uptake values (SUV) were quantified by region of interest (ROI) analysis. Radioactivity in the splee...', 'text_preview': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca'}, {'iri': 'ex:b_p002_0003', 'types': ['doco:Paragraph'], 'page': 2, 'score': 1, 'snippet': '... {}^{124} \\\\) I suffers limitations due to thyroid uptake following in vivo dehalogenation as well as decreased resolution. \\\\( ^{15} \\\\)  Chelator based...', 'text_preview': 'In recent years, a number of radioisotopes have been employed for antibody-based positron emission tomography (PET) and '}, {'iri': 'ex:b_p004_0008', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '...st injection, p.i.) were measured as standardized uptake values (SUVs) in the identified regions for all imaging data sets.', 'text_preview': 'MRI and PET images were manually co-registered using fiducial markers and anatomical information in software-co-registra'}, {'iri': 'ex:b_p005_0013', 'types': ['doco:Paragraph'], '...<truncated>"}}
{"timestamp": "2026-02-11T13:18:56.957829+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["Table 1", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:18:56.964128+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1901, "result_preview": "[{'iri': 'ex:b_p001_0009', 'types': ['doco:Paragraph'], 'page': 1, 'score': 2, 'snippet': '... stimulate immune responses. The Programmed Death-1 (PD-1) protein is an immunoinhibitory receptor expressed by activated cytotoxic T-lymphocytes (CTL...', 'text_preview': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca'}, {'iri': 'ex:b_p004_0012', 'types': ['doco:Paragraph'], 'page': 4, 'score': 2, 'snippet': '...es for nivolumab and nivolumab-DFO binding to hPD-1 are similar with a  \\\\( K_{D} \\\\)  of 3.10 nM for nivolumab and 3.75 nM for nivolumab-DFO (Fig. S4)....', 'text_preview': 'The  \\\\( K_{D} \\\\)  values for nivolumab and nivolumab-DFO binding to hPD-1 are similar with a  \\\\( K_{D} \\\\)  of 3.10 nM fo'}, {'iri': 'ex:b_p004_0015', 'types': ['deo:Caption'], 'page': 4, 'score': 2, 'snippet': 'Table 1\\n\\nInjected Doses of  \\\\( ^{89} \\\\) Zr-Nivolumab for Tracer only and Carrier-Added Studies in NH...', 'text_preview': 'Table 1  Injected Doses of  \\\\( ^{89} \\\\) Zr-Nivolumab for Tracer only and Carrier-Added Studies in NHPs.'}, {'iri': 'ex:b_p005_0010', 'types': ['doco:Paragraph'], 'page': 5, 'score': 2, 'snippet': '...<truncated>"}}
{"timestamp": "2026-02-11T13:19:11.065538+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p004_0015"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:19:11.066340+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 503, "result_preview": "{'iri': 'ex:b_p004_0015', 'properties': {'rdf:type': 'deo:Caption', 'kag:describes': 'ex:b_p004_0016', 'kag:fullText': 'Table 1\\n\\nInjected Doses of  \\\\( ^{89} \\\\) Zr-Nivolumab for Tracer only and Carrier-Added Studies in NHPs.', 'kag:hasBBox': '[[50, 738, 490, 762]]', 'kag:hasContentRef': 'caption:455f4b0b312a7592', 'kag:mainText': 'Table 1  Injected Doses of  \\\\( ^{89} \\\\) Zr-Nivolumab for Tracer only and Carrier-Added Studies in NHPs.', 'kag:pageNumber': '4', '_contained_by': ['ex:section_12']}}"}}
{"timestamp": "2026-02-11T13:19:11.066952+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p004_0012"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:19:11.067330+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 913, "result_preview": "{'iri': 'ex:b_p004_0012', 'properties': {'rdf:type': 'doco:Paragraph', 'kag:fullText': 'The  \\\\( K_{D} \\\\)  values for nivolumab and nivolumab-DFO binding to hPD-1 are similar with a  \\\\( K_{D} \\\\)  of 3.10 nM for nivolumab and 3.75 nM for nivolumab-DFO (Fig. S4). These are comparable to binding of nivolumab to cynoPD-1 with a  \\\\( K_{D} \\\\)  of 3.92 nM. \\\\( ^{19} \\\\)  Nivolumab-DFO was stored in single use vials (1 mL of 1.5 mg/mL) at  \\\\( -78^{\\\\circ}C \\\\)  and allowed to warm to room temperature prior to conjugation with  \\\\( {}^{89}Zr \\\\) . The purity after one freeze thaw cycle was unchang...<truncated>', 'kag:hasBBox': '[[499, 392, 933, 553]]', 'kag:hasContentRef': 'paragraph:7a79fe6cb5650ff8', 'kag:mainText': 'The  \\\\( K_{D} \\\\)  values for nivolumab and nivolumab-DFO binding to hPD-1 are similar with a  \\\\( K_{D} \\\\)  of 3.10 nM fo', 'kag:pageNumber': '4', '_contained_by': ['ex:section_11']}}"}}
{"timestamp": "2026-02-11T13:19:11.067707+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p005_0010"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:19:11.068139+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 956, "result_preview": "{'iri': 'ex:b_p005_0010', 'properties': {'rdf:type': 'doco:Paragraph', 'kag:fullText': 'purification conditions in future studies to isolate more  \\\\( {}^{89} \\\\) Zr-nivolumab with 0.25 M sodium acetate buffer as an alternative to PBS. Protein concentration was determined by NanoDrop and specific activity was calculated to be  \\\\( 352 \\\\pm 87 \\\\)  MBq/mg, see Table 1 for individual reaction data. Analysis by SEC determined the samples had good purity of >87% with the only detectable impurity being a single peak for a higher molecular weight species (HMWs) most likely an aggregate. The n...<truncated>', 'kag:hasBBox': '[[65, 569, 495, 728]]', 'kag:hasContentRef': 'paragraph:51b7d9a1fbada17d', 'kag:mainText': 'purification conditions in future studies to isolate more  \\\\( {}^{89} \\\\) Zr-nivolumab with 0.25 M sodium acetate buffer ', 'kag:pageNumber': '5', 'kag:refersTo': ['ex:b_p004_0016', 'ex:b_p005_0006'], '_contained_by': ['ex:section_12']}}"}}
{"timestamp": "2026-02-11T13:19:11.068602+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["SUV", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:19:11.069516+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1692, "result_preview": "[{'iri': 'ex:b_p001_0009', 'types': ['doco:Paragraph'], 'page': 1, 'score': 1, 'snippet': '...ection. Image-derived standardized uptake values (SUV) were quantified by region of interest (ROI) analysis. Radioactivity in the spleen was significa...', 'text_preview': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca'}, {'iri': 'ex:b_p004_0008', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '....i.) were measured as standardized uptake values (SUVs) in the identified regions for all imaging data sets.', 'text_preview': 'MRI and PET images were manually co-registered using fiducial markers and anatomical information in software-co-registra'}, {'iri': 'ex:b_p007_0004', 'types': ['deo:Caption'], 'page': 7, 'score': 1, 'snippet': 'Fig. 3. Image-derived biodistribution in NHPs (SUV): a Tracer only NHP. b Carrier-added 1 mg/kg nivolumab NHP. c Carrier-added 3 mg/kg nivolumab NH...', 'text_preview': 'Fig. 3. Image-derived biodistribution in NHPs (SUV): a Tracer only NHP. b Carrier-added 1 mg/kg nivolumab NHP. c Carrier'}, {'iri': 'ex:b_p007_0006', 'types': ['deo:Caption'], 'page': 7, 'score': 1, 'snippet...<truncated>"}}
{"timestamp": "2026-02-11T13:19:25.239650+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["spleen", "5"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:19:25.240937+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1935, "result_preview": "[{'iri': 'ex:b_p001_0009', 'types': ['doco:Paragraph'], 'page': 1, 'score': 1, 'snippet': '... of interest (ROI) analysis. Radioactivity in the spleen was significantly reduced by addition of excess nivolumab compared to the tracer only study a...', 'text_preview': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca'}, {'iri': 'ex:b_p004_0008', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '...d PET images (Fig. S6). The brain, thymus, heart, spleen, kidney, lung, liver, stomach wall, spine, and background area (e.g. muscle) were selected fo...', 'text_preview': 'MRI and PET images were manually co-registered using fiducial markers and anatomical information in software-co-registra'}, {'iri': 'ex:b_p005_0013', 'types': ['doco:Paragraph'], 'page': 5, 'score': 1, 'snippet': '...ealed that distribution of radioactivity into the spleen was reduced by the addition of unlabeled nivolumab compared to tracer only studies at all ima...', 'text_preview': 'PET derived images of NHPs (Fig. 3), revealed that distribution of radioactivity into the spleen was reduced by the addi'}, {'iri': 'ex:b_p005_0014', 'ty...<truncated>"}}
{"timestamp": "2026-02-11T13:19:25.241639+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_figure_info", "args": ["ex:b_p007_0004"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:19:25.241849+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_figure_info", "error": null, "result_size": 46, "result_preview": "{'error': 'Not a doco:Figure: ex:b_p007_0004'}"}}
{"timestamp": "2026-02-11T13:19:25.242213+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["liver", "3"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:19:25.243004+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 1158, "result_preview": "[{'iri': 'ex:b_p001_0009', 'types': ['doco:Paragraph'], 'page': 1, 'score': 1, 'snippet': '...the tracer only study at all imaging time points. Liver uptake of the radiotracer was consistent as a clearance organ with minimal signal from other t...', 'text_preview': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca'}, {'iri': 'ex:b_p002_0014', 'types': ['doco:Paragraph'], 'page': 2, 'score': 1, 'snippet': '...rth America, Inc. (Richmond, VA) with overnight delivery to Bristol-Myers Squibb (Princeton, NJ). The  \\\\( {}^{89} \\\\) Zr-nivolumab was', 'text_preview': '\\\\( ^{89} \\\\) Zr-oxalic acid was produced via the  \\\\( {}^{89} \\\\) Y(p,n) \\\\( ^{89} \\\\) Zr transmutation reaction on a cyclotr'}, {'iri': 'ex:b_p004_0008', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '.... The brain, thymus, heart, spleen, kidney, lung, liver, stomach wall, spine, and background area (e.g. muscle) were selected for calculating radioact...', 'text_preview': 'MRI and PET images were manually co-registered using fiducial markers and anatomical information in software-co-registra'}]"}}
{"timestamp": "2026-02-11T13:19:25.243395+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["kidney", "3"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:19:25.243957+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 780, "result_preview": "[{'iri': 'ex:b_p001_0009', 'types': ['doco:Paragraph'], 'page': 1, 'score': 1, 'snippet': '...om other tissues: lung, muscle, brain, heart, and kidney. The results indicate specific biodistribution to the spleen, which can be blocked by co-admi...', 'text_preview': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca'}, {'iri': 'ex:b_p004_0008', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '...ages (Fig. S6). The brain, thymus, heart, spleen, kidney, lung, liver, stomach wall, spine, and background area (e.g. muscle) were selected for calcul...', 'text_preview': 'MRI and PET images were manually co-registered using fiducial markers and anatomical information in software-co-registra'}]"}}
{"timestamp": "2026-02-11T13:19:35.056687+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "args": ["Fig", "10"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:19:35.058204+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_search", "error": null, "result_size": 3247, "result_preview": "[{'iri': 'ex:b_p004_0008', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '...ges, and applied to the co-registered PET images (Fig. S6). The brain, thymus, heart, spleen, kidney, lung, liver, stomach wall, spine, and background...', 'text_preview': 'MRI and PET images were manually co-registered using fiducial markers and anatomical information in software-co-registra'}, {'iri': 'ex:b_p004_0011', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '...etermined to be  \\\\( >95\\\\% \\\\)  with a CAR of 1.14 (Fig. S3). The chelate ratio was determined by LC-MS versus isotope dilution assay. \\\\( ^{30-32} \\\\)  F...', 'text_preview': 'Preparation of nivolumab-DFO in Scheme 1, step 1, was achieved through thiourea bond formation between the p-SCN-Bn-DFO '}, {'iri': 'ex:b_p004_0012', 'types': ['doco:Paragraph'], 'page': 4, 'score': 1, 'snippet': '...0 nM for nivolumab and 3.75 nM for nivolumab-DFO (Fig. S4). These are comparable to binding of nivolumab to cynoPD-1 with a  \\\\( K_{D} \\\\)  of 3.92 nM. ...', 'text_preview': 'The  \\\\( K_{D} \\\\)  values for nivolumab and nivolumab-DFO binding to hPD-1 are similar with a  \\\\( K_{D} \\\\)  of 3.10 nM fo'}, {'iri': 'ex:b_p005...<truncated>"}}
{"timestamp": "2026-02-11T13:19:35.059044+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p005_0013"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:19:35.059598+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 980, "result_preview": "{'iri': 'ex:b_p005_0013', 'properties': {'rdf:type': 'doco:Paragraph', 'kag:fullText': 'PET derived images of NHPs (Fig. 3), revealed that distribution of radioactivity into the spleen was reduced by the addition of unlabeled nivolumab compared to tracer only studies at all imaging time points ( \\\\( -82.5 \\\\pm 4.6\\\\% \\\\) ; range:  \\\\( -75.2 \\\\)  to  \\\\( -87.0\\\\% \\\\) , Table 2). Due to the small number of test animals, statistical data could not be provided. The PK for the two pre-dosed NHPs are reported in Table 3. In the PK analysis, the concentration of nivolumab in carrier-added of 1 mg/...<truncated>', 'kag:hasBBox': '[[66, 845, 496, 952], [515, 569, 945, 622]]', 'kag:hasContentRef': 'paragraph:e2c31485e9131fd4', 'kag:mainText': 'PET derived images of NHPs (Fig. 3), revealed that distribution of radioactivity into the spleen was reduced by the addi', 'kag:pageNumber': '5', 'kag:refersTo': ['ex:b_p007_0001', 'ex:b_p007_0002'], '_contained_by': ['ex:section_13']}}"}}
{"timestamp": "2026-02-11T13:19:35.060507+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "args": ["ex:b_p001_0009"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:19:35.060929+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "g_node_detail", "error": null, "result_size": 895, "result_preview": "{'iri': 'ex:b_p001_0009', 'properties': {'rdf:type': 'doco:Paragraph', 'kag:fullText': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify cancer cells and stimulate immune responses. The Programmed Death-1 (PD-1) protein is an immunoinhibitory receptor expressed by activated cytotoxic T-lymphocytes (CTL) that seek out and destroy cancer cells. Multiple cancer types express and upregulate the Programmed Death-Ligand 1 (PD-L1) and 2 (PD-L2) which bind to PD-1 as an immune escape mechanism. Nivolumab is a fully human ...<truncated>', 'kag:hasBBox': '[[347, 408, 944, 640]]', 'kag:hasContentRef': 'paragraph:20c93acd25b25b62', 'kag:mainText': 'Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca', 'kag:pageNumber': '1', '_contained_by': ['ex:section_2']}}"}}
{"timestamp": "2026-02-11T13:20:02.798449+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["nivolumab_01", "sio:ChemicalEntity", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.799139+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 164, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/nivolumab_01', 'class': 'http://semanticscience.org/resource/ChemicalEntity', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.800420+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_assert_type", "args": ["ex:nivolumab_01", "sio:Protein", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.800804+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_assert_type", "error": null, "result_size": 181, "result_preview": "{'operator': 'op_assert_type', 'node': 'http://la3d.local/kag/doc/nivolumab_01', 'class': 'http://semanticscience.org/resource/Protein', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:02.801363+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:nivolumab_01", "rdfs:label", "Nivolumab", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.801657+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 138, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:nivolumab_01', 'property': 'rdfs:label', 'value': 'Nivolumab', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.801988+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:nivolumab_01", "rdfs:comment", "Fully human IgG4 anti-PD-1 monoclonal antibody", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.802096+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 177, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:nivolumab_01', 'property': 'rdfs:comment', 'value': 'Fully human IgG4 anti-PD-1 monoclonal antibody', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.802330+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:nivolumab_01", "prov:wasDerivedFrom", "ex:b_p001_0009", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.802423+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 166, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:nivolumab_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p001_0009', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:02.803003+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["dfo_chelator_01", "sio:ChemicalEntity", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.803093+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 167, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/dfo_chelator_01', 'class': 'http://semanticscience.org/resource/ChemicalEntity', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.803386+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:dfo_chelator_01", "rdfs:label", "p-SCN-Bn-DFO", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.803481+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 144, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:dfo_chelator_01', 'property': 'rdfs:label', 'value': 'p-SCN-Bn-DFO', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.803895+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:dfo_chelator_01", "rdfs:comment", "1-(4-isothiocyanatophenyl)-3-[6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaecisoanet]thiourea", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.804032+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 268, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:dfo_chelator_01', 'property': 'rdfs:comment', 'value': '1-(4-isothiocyanatophenyl)-3-[6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaecisoanet]thiourea', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.804295+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:dfo_chelator_01", "prov:wasDerivedFrom", "ex:b_p002_0008", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.804383+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 169, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:dfo_chelator_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p002_0008', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:02.804585+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["zr89_01", "sio:ChemicalEntity", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.804650+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 159, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/zr89_01', 'class': 'http://semanticscience.org/resource/ChemicalEntity', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.804839+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_assert_type", "args": ["ex:zr89_01", "sio:Atom", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.804901+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_assert_type", "error": null, "result_size": 173, "result_preview": "{'operator': 'op_assert_type', 'node': 'http://la3d.local/kag/doc/zr89_01', 'class': 'http://semanticscience.org/resource/Atom', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:02.805080+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:zr89_01", "rdfs:label", "Zirconium-89", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.805154+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 136, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:zr89_01', 'property': 'rdfs:label', 'value': 'Zirconium-89', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.805396+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:zr89_01", "rdfs:comment", "Radioisotope for PET imaging", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.805470+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 154, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:zr89_01', 'property': 'rdfs:comment', 'value': 'Radioisotope for PET imaging', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.805625+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:zr89_01", "prov:wasDerivedFrom", "ex:b_p003_0003", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.805692+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 161, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:zr89_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p003_0003', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:02.805843+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["nivolumab_dfo_01", "sio:ChemicalEntity", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.805909+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 168, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/nivolumab_dfo_01', 'class': 'http://semanticscience.org/resource/ChemicalEntity', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.806082+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:nivolumab_dfo_01", "rdfs:label", "Nivolumab-DFO conjugate", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.806157+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 156, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:nivolumab_dfo_01', 'property': 'rdfs:label', 'value': 'Nivolumab-DFO conjugate', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.806311+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:nivolumab_dfo_01", "rdfs:comment", "Nivolumab conjugated with p-SCN-Bn-DFO via thiourea linkage", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.806380+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 194, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:nivolumab_dfo_01', 'property': 'rdfs:comment', 'value': 'Nivolumab conjugated with p-SCN-Bn-DFO via thiourea linkage', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.806529+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:nivolumab_dfo_01", "prov:wasDerivedFrom", "ex:b_p004_0011", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.806594+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 170, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:nivolumab_dfo_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0011', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:02.806744+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:nivolumab_dfo_01", "sio:has-component-part", "ex:nivolumab_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.806851+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 174, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:nivolumab_dfo_01', 'predicate': 'sio:has-component-part', 'object': 'ex:nivolumab_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:02.806994+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:nivolumab_dfo_01", "sio:has-component-part", "ex:dfo_chelator_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.807045+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 177, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:nivolumab_dfo_01', 'predicate': 'sio:has-component-part', 'object': 'ex:dfo_chelator_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:02.807190+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["zr89_nivolumab_01", "sio:ChemicalEntity", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.807246+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 169, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/zr89_nivolumab_01', 'class': 'http://semanticscience.org/resource/ChemicalEntity', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.807382+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:zr89_nivolumab_01", "rdfs:label", "89Zr-Nivolumab", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.807442+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 148, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:zr89_nivolumab_01', 'property': 'rdfs:label', 'value': '89Zr-Nivolumab', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.807673+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:zr89_nivolumab_01", "rdfs:comment", "Zirconium-89 labeled Nivolumab PET tracer", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.807728+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 177, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:zr89_nivolumab_01', 'property': 'rdfs:comment', 'value': 'Zirconium-89 labeled Nivolumab PET tracer', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:02.807908+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:zr89_nivolumab_01", "prov:wasDerivedFrom", "ex:b_p004_0014", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.807959+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 171, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:zr89_nivolumab_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0014', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:02.808106+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:zr89_nivolumab_01", "sio:has-component-part", "ex:nivolumab_dfo_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.808157+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 179, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:zr89_nivolumab_01', 'predicate': 'sio:has-component-part', 'object': 'ex:nivolumab_dfo_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:02.808343+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:zr89_nivolumab_01", "sio:has-component-part", "ex:zr89_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:02.808396+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 170, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:zr89_nivolumab_01', 'predicate': 'sio:has-component-part', 'object': 'ex:zr89_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.333170+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["pd1_protein_01", "sio:Protein", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.333596+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 159, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/pd1_protein_01', 'class': 'http://semanticscience.org/resource/Protein', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.334173+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:pd1_protein_01", "rdfs:label", "PD-1", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.334362+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 135, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:pd1_protein_01', 'property': 'rdfs:label', 'value': 'PD-1', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.334694+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:pd1_protein_01", "rdfs:comment", "Programmed Death-1 protein, immunoinhibitory receptor expressed by activated cytotoxic T-lymphocytes", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.334802+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 233, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:pd1_protein_01', 'property': 'rdfs:comment', 'value': 'Programmed Death-1 protein, immunoinhibitory receptor expressed by activated cytotoxic T-lymphocytes', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.335197+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:pd1_protein_01", "prov:wasDerivedFrom", "ex:b_p001_0009", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.335330+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 168, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:pd1_protein_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p001_0009', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.335637+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:nivolumab_01", "sio:has-target", "ex:pd1_protein_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.335726+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 164, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:nivolumab_01', 'predicate': 'sio:has-target', 'object': 'ex:pd1_protein_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.336002+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["pdl1_protein_01", "sio:Protein", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.336088+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 160, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/pdl1_protein_01', 'class': 'http://semanticscience.org/resource/Protein', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.336324+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:pdl1_protein_01", "rdfs:label", "PD-L1", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.336416+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 137, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:pdl1_protein_01', 'property': 'rdfs:label', 'value': 'PD-L1', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.336630+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:pdl1_protein_01", "rdfs:comment", "Programmed Death-Ligand 1, binds to PD-1 as immune escape mechanism", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.336709+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 201, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:pdl1_protein_01', 'property': 'rdfs:comment', 'value': 'Programmed Death-Ligand 1, binds to PD-1 as immune escape mechanism', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.336887+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:pdl1_protein_01", "prov:wasDerivedFrom", "ex:b_p001_0009", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.336962+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 169, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:pdl1_protein_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p001_0009', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.337124+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["pdl2_protein_01", "sio:Protein", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.337179+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 160, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/pdl2_protein_01', 'class': 'http://semanticscience.org/resource/Protein', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.337329+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:pdl2_protein_01", "rdfs:label", "PD-L2", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.337391+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 137, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:pdl2_protein_01', 'property': 'rdfs:label', 'value': 'PD-L2', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.337622+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:pdl2_protein_01", "rdfs:comment", "Programmed Death-Ligand 2, binds to PD-1 as immune escape mechanism", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.337720+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 201, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:pdl2_protein_01', 'property': 'rdfs:comment', 'value': 'Programmed Death-Ligand 2, binds to PD-1 as immune escape mechanism', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.337920+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:pdl2_protein_01", "prov:wasDerivedFrom", "ex:b_p001_0009", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.337988+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 169, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:pdl2_protein_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p001_0009', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.338154+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["car_measurement_01", "qudt:QuantityValue", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.338213+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 161, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/car_measurement_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.338379+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:car_measurement_01", "rdfs:label", "CAR of Nivolumab-DFO", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.338445+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 155, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:car_measurement_01', 'property': 'rdfs:label', 'value': 'CAR of Nivolumab-DFO', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.338621+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:car_measurement_01", "qudt:numericValue", "1.14", "xsd:double", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.338725+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 146, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:car_measurement_01', 'property': 'qudt:numericValue', 'value': '1.14', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.338895+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:car_measurement_01", "rdfs:comment", "Chelator-to-antibody ratio determined by LC-MS", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.338962+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 183, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:car_measurement_01', 'property': 'rdfs:comment', 'value': 'Chelator-to-antibody ratio determined by LC-MS', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.339109+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:nivolumab_dfo_01", "sio:has-measurement-value", "ex:car_measurement_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.339173+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 183, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:nivolumab_dfo_01', 'predicate': 'sio:has-measurement-value', 'object': 'ex:car_measurement_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.339325+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:car_measurement_01", "prov:wasDerivedFrom", "ex:b_p004_0011", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.339381+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 172, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:car_measurement_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0011', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.339557+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["conjugation_yield_01", "qudt:QuantityValue", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.339621+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 163, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/conjugation_yield_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.339788+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:conjugation_yield_01", "rdfs:label", "Conjugation yield", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.339858+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 154, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:conjugation_yield_01', 'property': 'rdfs:label', 'value': 'Conjugation yield', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.340035+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:conjugation_yield_01", "qudt:numericValue", "88", "xsd:double", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.340112+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 148, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:conjugation_yield_01', 'property': 'qudt:numericValue', 'value': '88.0', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.340267+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:conjugation_yield_01", "qudt:unit", "percent", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.340330+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 143, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:conjugation_yield_01', 'property': 'qudt:unit', 'value': 'percent', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.340484+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:conjugation_yield_01", "rdfs:comment", "Yield of Nivolumab-DFO after purification (8.8 mg from 10 mg parent)", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.340551+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 207, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:conjugation_yield_01', 'property': 'rdfs:comment', 'value': 'Yield of Nivolumab-DFO after purification (8.8 mg from 10 mg parent)', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.340699+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:nivolumab_dfo_01", "sio:has-measurement-value", "ex:conjugation_yield_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.340762+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 185, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:nivolumab_dfo_01', 'predicate': 'sio:has-measurement-value', 'object': 'ex:conjugation_yield_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.340924+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:conjugation_yield_01", "prov:wasDerivedFrom", "ex:b_p004_0011", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.340985+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 174, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:conjugation_yield_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0011', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.341132+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["purity_measurement_01", "qudt:QuantityValue", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.341192+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 164, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/purity_measurement_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.341350+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:purity_measurement_01", "rdfs:label", "Purity of Nivolumab-DFO", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.341418+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 161, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:purity_measurement_01', 'property': 'rdfs:label', 'value': 'Purity of Nivolumab-DFO', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.341567+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:purity_measurement_01", "qudt:numericValue", "95", "xsd:double", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.341637+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 149, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:purity_measurement_01', 'property': 'qudt:numericValue', 'value': '95.0', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.341783+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:purity_measurement_01", "qudt:unit", "percent", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.341847+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 144, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:purity_measurement_01', 'property': 'qudt:unit', 'value': 'percent', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.341995+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:purity_measurement_01", "rdfs:comment", "Purity >95%", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.342058+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 151, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:purity_measurement_01', 'property': 'rdfs:comment', 'value': 'Purity >95%', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.342217+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:nivolumab_dfo_01", "sio:has-measurement-value", "ex:purity_measurement_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.342279+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 186, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:nivolumab_dfo_01', 'predicate': 'sio:has-measurement-value', 'object': 'ex:purity_measurement_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.342425+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:purity_measurement_01", "prov:wasDerivedFrom", "ex:b_p004_0011", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.342485+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 175, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:purity_measurement_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0011', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.342630+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["radiochemical_yield_01", "qudt:QuantityValue", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.342687+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 165, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/radiochemical_yield_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.342862+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:radiochemical_yield_01", "rdfs:label", "Radiochemical yield", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.343016+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 158, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:radiochemical_yield_01', 'property': 'rdfs:label', 'value': 'Radiochemical yield', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.343180+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:radiochemical_yield_01", "qudt:numericValue", "53", "xsd:double", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.343263+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 150, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:radiochemical_yield_01', 'property': 'qudt:numericValue', 'value': '53.0', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.343463+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:radiochemical_yield_01", "qudt:unit", "percent", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.343521+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 145, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:radiochemical_yield_01', 'property': 'qudt:unit', 'value': 'percent', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.343649+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:radiochemical_yield_01", "rdfs:comment", "Radiochemical yield 53 \u00b1 8% (non-decay-corrected)", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.343704+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 190, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:radiochemical_yield_01', 'property': 'rdfs:comment', 'value': 'Radiochemical yield 53 \u00b1 8% (non-decay-corrected)', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.343990+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:zr89_nivolumab_01", "sio:has-measurement-value", "ex:radiochemical_yield_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.344047+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 188, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:zr89_nivolumab_01', 'predicate': 'sio:has-measurement-value', 'object': 'ex:radiochemical_yield_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.344196+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:radiochemical_yield_01", "prov:wasDerivedFrom", "ex:b_p004_0014", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.344254+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 176, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:radiochemical_yield_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0014', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.344381+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["specific_activity_01", "qudt:QuantityValue", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.344428+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 163, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/specific_activity_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.344559+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:specific_activity_01", "rdfs:label", "Specific activity", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.344614+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 154, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:specific_activity_01', 'property': 'rdfs:label', 'value': 'Specific activity', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.344877+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:specific_activity_01", "qudt:numericValue", "352", "xsd:double", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.344934+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 149, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:specific_activity_01', 'property': 'qudt:numericValue', 'value': '352.0', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.345123+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:specific_activity_01", "qudt:unit", "MBq/mg", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.345180+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 142, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:specific_activity_01', 'property': 'qudt:unit', 'value': 'MBq/mg', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.345323+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:specific_activity_01", "rdfs:comment", "Specific activity 352 \u00b1 87 MBq/mg", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.345397+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 172, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:specific_activity_01', 'property': 'rdfs:comment', 'value': 'Specific activity 352 \u00b1 87 MBq/mg', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:36.345666+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:zr89_nivolumab_01", "sio:has-measurement-value", "ex:specific_activity_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.345725+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 186, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:zr89_nivolumab_01', 'predicate': 'sio:has-measurement-value', 'object': 'ex:specific_activity_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:36.345867+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:specific_activity_01", "prov:wasDerivedFrom", "ex:b_p005_0010", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:36.345929+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 174, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:specific_activity_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p005_0010', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:58.794751+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["kd_nivolumab_01", "qudt:QuantityValue", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.795083+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 158, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/kd_nivolumab_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.795486+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:kd_nivolumab_01", "rdfs:label", "KD of Nivolumab to PD-1", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.795610+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 155, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:kd_nivolumab_01', 'property': 'rdfs:label', 'value': 'KD of Nivolumab to PD-1', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.796008+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:kd_nivolumab_01", "qudt:numericValue", "3.10", "xsd:double", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.796201+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 142, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:kd_nivolumab_01', 'property': 'qudt:numericValue', 'value': '3.1', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.796574+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:kd_nivolumab_01", "qudt:unit", "nM", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.796763+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 133, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:kd_nivolumab_01', 'property': 'qudt:unit', 'value': 'nM', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.797027+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:kd_nivolumab_01", "rdfs:comment", "Dissociation constant for Nivolumab binding to human PD-1, measured by SPR", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.797130+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 208, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:kd_nivolumab_01', 'property': 'rdfs:comment', 'value': 'Dissociation constant for Nivolumab binding to human PD-1, measured by SPR', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.797382+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:nivolumab_01", "sio:has-measurement-value", "ex:kd_nivolumab_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.797465+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 176, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:nivolumab_01', 'predicate': 'sio:has-measurement-value', 'object': 'ex:kd_nivolumab_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:58.797664+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:kd_nivolumab_01", "prov:wasDerivedFrom", "ex:b_p004_0012", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.797736+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 169, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:kd_nivolumab_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0012', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:58.797966+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["kd_nivolumab_dfo_01", "qudt:QuantityValue", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.798032+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 162, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/kd_nivolumab_dfo_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.798220+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:kd_nivolumab_dfo_01", "rdfs:label", "KD of Nivolumab-DFO to PD-1", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.798293+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 163, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:kd_nivolumab_dfo_01', 'property': 'rdfs:label', 'value': 'KD of Nivolumab-DFO to PD-1', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.798679+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:kd_nivolumab_dfo_01", "qudt:numericValue", "3.75", "xsd:double", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.798808+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 147, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:kd_nivolumab_dfo_01', 'property': 'qudt:numericValue', 'value': '3.75', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.799040+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:kd_nivolumab_dfo_01", "qudt:unit", "nM", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.799192+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 137, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:kd_nivolumab_dfo_01', 'property': 'qudt:unit', 'value': 'nM', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.799394+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:kd_nivolumab_dfo_01", "rdfs:comment", "Dissociation constant for Nivolumab-DFO binding to human PD-1, measured by SPR", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.799486+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 216, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:kd_nivolumab_dfo_01', 'property': 'rdfs:comment', 'value': 'Dissociation constant for Nivolumab-DFO binding to human PD-1, measured by SPR', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.799641+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:nivolumab_dfo_01", "sio:has-measurement-value", "ex:kd_nivolumab_dfo_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.799708+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 184, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:nivolumab_dfo_01', 'predicate': 'sio:has-measurement-value', 'object': 'ex:kd_nivolumab_dfo_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:58.799852+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:kd_nivolumab_dfo_01", "prov:wasDerivedFrom", "ex:b_p004_0012", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.799911+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 173, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:kd_nivolumab_dfo_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0012', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:58.800047+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["activity_range_01", "qudt:QuantityValue", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.800101+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 160, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/activity_range_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.800239+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:activity_range_01", "rdfs:label", "Activity of 89Zr-Nivolumab", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.800299+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 160, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:activity_range_01', 'property': 'rdfs:label', 'value': 'Activity of 89Zr-Nivolumab', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.800599+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:activity_range_01", "qudt:numericValue", "283", "xsd:double", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.800675+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 146, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:activity_range_01', 'property': 'qudt:numericValue', 'value': '283.0', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.800811+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:activity_range_01", "qudt:unit", "MBq", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.800872+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 136, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:activity_range_01', 'property': 'qudt:unit', 'value': 'MBq', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.801011+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:activity_range_01", "rdfs:comment", "Activity range 225-341 MBq (mean ~283 MBq)", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.801070+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 178, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:activity_range_01', 'property': 'rdfs:comment', 'value': 'Activity range 225-341 MBq (mean ~283 MBq)', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.801280+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:zr89_nivolumab_01", "sio:has-measurement-value", "ex:activity_range_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.801336+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 183, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:zr89_nivolumab_01', 'predicate': 'sio:has-measurement-value', 'object': 'ex:activity_range_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:58.801507+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:activity_range_01", "prov:wasDerivedFrom", "ex:b_p004_0014", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.801562+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 171, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:activity_range_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0014', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:58.801694+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["injected_dose_01", "qudt:QuantityValue", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.801744+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 159, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/injected_dose_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.801879+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:injected_dose_01", "rdfs:label", "Injected dose in NHP", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.801938+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 153, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:injected_dose_01', 'property': 'rdfs:label', 'value': 'Injected dose in NHP', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.802240+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:injected_dose_01", "qudt:numericValue", "54.5", "xsd:double", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.802337+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 144, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:injected_dose_01', 'property': 'qudt:numericValue', 'value': '54.5', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.802480+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:injected_dose_01", "qudt:unit", "MBq", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.802544+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 135, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:injected_dose_01', 'property': 'qudt:unit', 'value': 'MBq', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.802692+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:injected_dose_01", "rdfs:comment", "Injected dose 54.5 \u00b1 11.0 MBq in non-human primates", "None", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.802757+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 186, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:injected_dose_01', 'property': 'rdfs:comment', 'value': 'Injected dose 54.5 \u00b1 11.0 MBq in non-human primates', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:20:58.802992+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:zr89_nivolumab_01", "sio:has-measurement-value", "ex:injected_dose_01", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.803082+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 182, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:zr89_nivolumab_01', 'predicate': 'sio:has-measurement-value', 'object': 'ex:injected_dose_01', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:20:58.803250+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:injected_dose_01", "prov:wasDerivedFrom", "ex:b_p004_0007", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:20:58.803315+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 170, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:injected_dose_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0007', 'graph': 'entity', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.781948+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["claim_spleen_uptake_01", "sio:Statement", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.782234+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 168, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/claim_spleen_uptake_01', 'class': 'http://semanticscience.org/resource/Statement', 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.782883+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:claim_spleen_uptake_01", "rdfs:label", "Spleen uptake reduction with carrier-added nivolumab", "None", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.782995+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 190, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:claim_spleen_uptake_01', 'property': 'rdfs:label', 'value': 'Spleen uptake reduction with carrier-added nivolumab', 'removed': 0, 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.783317+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:claim_spleen_uptake_01", "rdfs:comment", "Distribution of radioactivity into the spleen was reduced by 82.5 \u00b1 4.6% (range: -75.2 to -87.0%) by addition of unlabeled nivolumab compared to tracer only studies at all imaging time points", "None", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.783392+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 331, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:claim_spleen_uptake_01', 'property': 'rdfs:comment', 'value': 'Distribution of radioactivity into the spleen was reduced by 82.5 \u00b1 4.6% (range: -75.2 to -87.0%) by addition of unlabeled nivolumab compared to tracer only studies at all imaging time points', 'removed': 0, 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.783582+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_spleen_uptake_01", "prov:wasDerivedFrom", "ex:b_p005_0013", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.783649+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 175, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_spleen_uptake_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p005_0013', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.784000+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_spleen_uptake_01", "sio:is-about", "ex:zr89_nivolumab_01", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.784143+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 174, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_spleen_uptake_01', 'predicate': 'sio:is-about', 'object': 'ex:zr89_nivolumab_01', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.784397+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["claim_binding_preservation_01", "sio:Statement", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.784463+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 175, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/claim_binding_preservation_01', 'class': 'http://semanticscience.org/resource/Statement', 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.784663+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:claim_binding_preservation_01", "rdfs:label", "Binding affinity preserved after DFO conjugation", "None", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.784738+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 193, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:claim_binding_preservation_01', 'property': 'rdfs:label', 'value': 'Binding affinity preserved after DFO conjugation', 'removed': 0, 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.785028+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:claim_binding_preservation_01", "rdfs:comment", "KD values for nivolumab (3.10 nM) and nivolumab-DFO (3.75 nM) binding to hPD-1 are similar, indicating that DFO conjugation does not significantly affect binding affinity", "None", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.785086+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 317, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:claim_binding_preservation_01', 'property': 'rdfs:comment', 'value': 'KD values for nivolumab (3.10 nM) and nivolumab-DFO (3.75 nM) binding to hPD-1 are similar, indicating that DFO conjugation does not significantly affect binding affinity', 'removed': 0, 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.785266+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_binding_preservation_01", "prov:wasDerivedFrom", "ex:b_p004_0012", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.785341+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 182, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_binding_preservation_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0012', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.785491+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_binding_preservation_01", "sio:is-about", "ex:nivolumab_dfo_01", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.785546+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 180, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_binding_preservation_01', 'predicate': 'sio:is-about', 'object': 'ex:nivolumab_dfo_01', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.785684+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_binding_preservation_01", "sio:is-about", "ex:kd_nivolumab_01", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.785736+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 179, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_binding_preservation_01', 'predicate': 'sio:is-about', 'object': 'ex:kd_nivolumab_01', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.785899+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_binding_preservation_01", "sio:is-about", "ex:kd_nivolumab_dfo_01", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.785966+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 183, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_binding_preservation_01', 'predicate': 'sio:is-about', 'object': 'ex:kd_nivolumab_dfo_01', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.786130+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["claim_radiolabeling_01", "sio:Statement", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.786183+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 168, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/claim_radiolabeling_01', 'class': 'http://semanticscience.org/resource/Statement', 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.786370+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:claim_radiolabeling_01", "rdfs:label", "Successful 89Zr radiolabeling of nivolumab-DFO", "None", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.786427+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 184, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:claim_radiolabeling_01', 'property': 'rdfs:label', 'value': 'Successful 89Zr radiolabeling of nivolumab-DFO', 'removed': 0, 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.786604+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:claim_radiolabeling_01", "rdfs:comment", "89Zr-labeling yielded 225-341 MBq with moderate radiochemical yield of 53 \u00b1 8% (non-decay-corrected) and specific activity of 352 \u00b1 87 MBq/mg", "None", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.786743+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 281, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:claim_radiolabeling_01', 'property': 'rdfs:comment', 'value': '89Zr-labeling yielded 225-341 MBq with moderate radiochemical yield of 53 \u00b1 8% (non-decay-corrected) and specific activity of 352 \u00b1 87 MBq/mg', 'removed': 0, 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.786929+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_radiolabeling_01", "prov:wasDerivedFrom", "ex:b_p004_0014", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.787002+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 175, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_radiolabeling_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0014', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.787160+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_radiolabeling_01", "prov:wasDerivedFrom", "ex:b_p005_0010", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.787215+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 175, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_radiolabeling_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p005_0010', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.787502+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_radiolabeling_01", "sio:is-about", "ex:zr89_nivolumab_01", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.787569+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 174, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_radiolabeling_01', 'predicate': 'sio:is-about', 'object': 'ex:zr89_nivolumab_01', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.787756+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_radiolabeling_01", "sio:is-about", "ex:radiochemical_yield_01", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.787809+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 179, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_radiolabeling_01', 'predicate': 'sio:is-about', 'object': 'ex:radiochemical_yield_01', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.787963+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_radiolabeling_01", "sio:is-about", "ex:specific_activity_01", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.788013+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 177, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_radiolabeling_01', 'predicate': 'sio:is-about', 'object': 'ex:specific_activity_01', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.788166+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["claim_conjugation_01", "sio:Statement", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.788214+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 166, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/claim_conjugation_01', 'class': 'http://semanticscience.org/resource/Statement', 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.788357+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:claim_conjugation_01", "rdfs:label", "Efficient DFO conjugation to nivolumab", "None", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.788413+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 174, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:claim_conjugation_01', 'property': 'rdfs:label', 'value': 'Efficient DFO conjugation to nivolumab', 'removed': 0, 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.788614+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:claim_conjugation_01", "rdfs:comment", "Nivolumab-DFO was isolated with 88% yield (8.8 mg from 10 mg parent), >95% purity, and CAR of 1.14", "None", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.788690+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 236, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:claim_conjugation_01', 'property': 'rdfs:comment', 'value': 'Nivolumab-DFO was isolated with 88% yield (8.8 mg from 10 mg parent), >95% purity, and CAR of 1.14', 'removed': 0, 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.788834+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_conjugation_01", "prov:wasDerivedFrom", "ex:b_p004_0011", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.788955+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 173, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_conjugation_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p004_0011', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.789084+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_conjugation_01", "sio:is-about", "ex:nivolumab_dfo_01", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.789139+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 171, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_conjugation_01', 'predicate': 'sio:is-about', 'object': 'ex:nivolumab_dfo_01', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.789262+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_conjugation_01", "sio:is-about", "ex:conjugation_yield_01", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.789320+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 175, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_conjugation_01', 'predicate': 'sio:is-about', 'object': 'ex:conjugation_yield_01', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.789454+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_conjugation_01", "sio:is-about", "ex:car_measurement_01", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.789538+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 173, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_conjugation_01', 'predicate': 'sio:is-about', 'object': 'ex:car_measurement_01', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.789697+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "args": ["claim_pet_imaging_01", "sio:Statement", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.789757+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_create_entity", "error": null, "result_size": 166, "result_preview": "{'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/claim_pet_imaging_01', 'class': 'http://semanticscience.org/resource/Statement', 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.789900+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:claim_pet_imaging_01", "rdfs:label", "89Zr-nivolumab enables PET imaging in non-human primates", "None", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.789960+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 192, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:claim_pet_imaging_01', 'property': 'rdfs:label', 'value': '89Zr-nivolumab enables PET imaging in non-human primates', 'removed': 0, 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.790112+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "args": ["ex:claim_pet_imaging_01", "rdfs:comment", "89Zr-nivolumab was successfully used for PET imaging in healthy non-human primates, showing specific biodistribution to spleen and liver with reduced background in other tissues", "None", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.790187+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_literal", "error": null, "result_size": 315, "result_preview": "{'operator': 'op_set_literal', 'node': 'ex:claim_pet_imaging_01', 'property': 'rdfs:comment', 'value': '89Zr-nivolumab was successfully used for PET imaging in healthy non-human primates, showing specific biodistribution to spleen and liver with reduced background in other tissues', 'removed': 0, 'graph': 'claim'}"}}
{"timestamp": "2026-02-11T13:21:33.790333+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_pet_imaging_01", "prov:wasDerivedFrom", "ex:b_p001_0009", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.790389+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 173, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_pet_imaging_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p001_0009', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.790535+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_pet_imaging_01", "prov:wasDerivedFrom", "ex:b_p005_0013", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.790585+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 173, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_pet_imaging_01', 'predicate': 'prov:wasDerivedFrom', 'object': 'ex:b_p005_0013', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.790869+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "args": ["ex:claim_pet_imaging_01", "sio:is-about", "ex:zr89_nivolumab_01", "claim"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.790919+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_add_link", "error": null, "result_size": 172, "result_preview": "{'operator': 'op_add_link', 'subject': 'ex:claim_pet_imaging_01', 'predicate': 'sio:is-about', 'object': 'ex:zr89_nivolumab_01', 'graph': 'claim', 'already_present': False}"}}
{"timestamp": "2026-02-11T13:21:33.791074+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "validate_graph", "args": ["all"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:33.849854+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "validate_graph", "error": null, "result_size": 576, "result_preview": "{'conforms': False, 'layers': {'entity': {'conforms': False, 'total_violations': 2, 'violations': [{'node': 'http://la3d.local/kag/doc/car_measurement_01', 'message': \"MeasuredValue must have exactly one qudt:unit. Fix: op_set_link(mv_iri, 'qudt:unit', 'unit:ANGSTROM').\"}, {'node': 'http://la3d.local/kag/doc/car_measurement_01', 'message': \"QuantityValue must have exactly one qudt:unit. Fix: op_set_link(qv_iri, 'qudt:unit', 'unit:DEG_C').\"}]}, 'claim': {'conforms': True, 'total_violations': 0}, 'cross_graph': {'conforms': True, 'ungrounded': [], 'total_ungrounded': 0}}}"}}
{"timestamp": "2026-02-11T13:21:52.285994+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "args": ["ex:car_measurement_01", "qudt:unit", "unit:UNITLESS", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:52.286216+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "error": null, "result_size": 149, "result_preview": "{'operator': 'op_set_link', 'subject': 'ex:car_measurement_01', 'predicate': 'qudt:unit', 'object': 'unit:UNITLESS', 'removed': 0, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:21:52.286573+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "args": ["ex:conjugation_yield_01", "qudt:unit", "unit:PERCENT", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:52.286704+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "error": null, "result_size": 150, "result_preview": "{'operator': 'op_set_link', 'subject': 'ex:conjugation_yield_01', 'predicate': 'qudt:unit', 'object': 'unit:PERCENT', 'removed': 1, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:21:52.286972+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "args": ["ex:purity_measurement_01", "qudt:unit", "unit:PERCENT", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:52.287078+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "error": null, "result_size": 151, "result_preview": "{'operator': 'op_set_link', 'subject': 'ex:purity_measurement_01', 'predicate': 'qudt:unit', 'object': 'unit:PERCENT', 'removed': 1, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:21:52.287257+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "args": ["ex:radiochemical_yield_01", "qudt:unit", "unit:PERCENT", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:52.287332+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "error": null, "result_size": 152, "result_preview": "{'operator': 'op_set_link', 'subject': 'ex:radiochemical_yield_01', 'predicate': 'qudt:unit', 'object': 'unit:PERCENT', 'removed': 1, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:21:52.287474+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "args": ["ex:specific_activity_01", "qudt:unit", "unit:MegaBQ-PER-GM", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:52.287534+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "error": null, "result_size": 156, "result_preview": "{'operator': 'op_set_link', 'subject': 'ex:specific_activity_01', 'predicate': 'qudt:unit', 'object': 'unit:MegaBQ-PER-GM', 'removed': 1, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:21:52.287681+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "args": ["ex:kd_nivolumab_01", "qudt:unit", "unit:NanoMOL-PER-L", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:52.287817+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "error": null, "result_size": 151, "result_preview": "{'operator': 'op_set_link', 'subject': 'ex:kd_nivolumab_01', 'predicate': 'qudt:unit', 'object': 'unit:NanoMOL-PER-L', 'removed': 1, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:21:52.287966+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "args": ["ex:kd_nivolumab_dfo_01", "qudt:unit", "unit:NanoMOL-PER-L", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:52.288040+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "error": null, "result_size": 155, "result_preview": "{'operator': 'op_set_link', 'subject': 'ex:kd_nivolumab_dfo_01', 'predicate': 'qudt:unit', 'object': 'unit:NanoMOL-PER-L', 'removed': 1, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:21:52.288287+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "args": ["ex:activity_range_01", "qudt:unit", "unit:MegaBQ", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:52.288350+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "error": null, "result_size": 146, "result_preview": "{'operator': 'op_set_link', 'subject': 'ex:activity_range_01', 'predicate': 'qudt:unit', 'object': 'unit:MegaBQ', 'removed': 1, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:21:52.288469+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "args": ["ex:injected_dose_01", "qudt:unit", "unit:MegaBQ", "entity"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:52.288521+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "op_set_link", "error": null, "result_size": 145, "result_preview": "{'operator': 'op_set_link', 'subject': 'ex:injected_dose_01', 'predicate': 'qudt:unit', 'object': 'unit:MegaBQ', 'removed': 1, 'graph': 'entity'}"}}
{"timestamp": "2026-02-11T13:21:52.288631+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "validate_graph", "args": ["all"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:21:52.338074+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "validate_graph", "error": null, "result_size": 211, "result_preview": "{'conforms': True, 'layers': {'entity': {'conforms': True, 'total_violations': 0}, 'claim': {'conforms': True, 'total_violations': 0}, 'cross_graph': {'conforms': True, 'ungrounded': [], 'total_ungrounded': 0}}}"}}
{"timestamp": "2026-02-11T13:22:13.706791+00:00", "event_type": "tool_call", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "finalize_graph", "args": ["\nExtracted key entities, measurements, and claims from paper on 89Zr-Nivolumab PET imaging:\n\nCHEMICAL ENTITIES (5):\n- Nivolumab: Anti-PD-1 monoclonal antibody\n- p-SCN-Bn-DFO: Bifunctional chelator\n- Zirconium-89: PET radioisotope\n- Nivolumab-DFO: Conjugate (CAR 1.14, 88% yield, >95% purity)\n- 89Zr-N...<truncated>"], "kwargs": {}}}
{"timestamp": "2026-02-11T13:22:13.768689+00:00", "event_type": "tool_result", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "tool": "finalize_graph", "error": null, "result_size": 371, "result_preview": "{'status': 'READY', 'message': \"All graphs conform. Call SUBMIT(answer='\\nExtracted key entities, measurements, and claims from paper on 89Zr-Nivolumab P...')\", 'conforms': True, 'layers': {'entity': {'conforms': True, 'total_violations': 0}, 'claim': {'conforms': True, 'total_violations': 0}, 'cross_graph': {'conforms': True, 'ungrounded': [], 'total_ungrounded': 0}}}"}}
{"timestamp": "2026-02-11T13:22:13.787478+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 1, "reasoning": "I need to extract key entities, measurements, and claims from a scientific document. Let me start by exploring the document structure to understand what I'm working with.\n\nFrom the preview, I can see:\n- This appears to be a scientific paper about Nivolumab conjugation with DFO (likely a radiolabeling study)\n- The document has 18 sections, 86 paragraphs, 10 figures, 3 tables\n- Sections include Introduction, Experimental methods, etc.\n\nMy approach:\n1. First, explore the document structure to understand the content\n2. Search for key chemical entities, measurements, and experimental data\n3. Create entities in G_entity for chemicals, measurements, etc.\n4. Create claims in G_claim for scientific findings\n5. Validate and finalize\n\nLet me start by examining the document sections and getting a sense of the content.", "code": "# First, let's explore the document structure\nprint(\"=== EXPLORING DOCUMENT STRUCTURE ===\\n\")\n\n# Get the context to see what we're working with\nprint(\"Context preview:\")\nprint(context[:500])\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Let's look at the abstract and introduction to understand the paper\nabstract_content = g_section_content(\"ex:section_2\")\nprint(\"Abstract section content:\")\nprint(json.dumps(abstract_content, indent=2))", "output": "=== EXPLORING DOCUMENT STRUCTURE ===\n\nContext preview:\n## Document Graph Overview\nTriples: 1133 | Sections: 18 | Paragraphs: 86 | Figures: 10 | Tables: 3 | Formulas: 0 | Bib refs: 37\n\n## Sections\n- ex:section_3: \"## 1. Introduction\" (p1, 7 children) [deo:Introduction]\n- ex:section_2: \"## A B S T R A C T\" (p1, 2 children)\n- ex:section_1: \"## ARTICLE INFO\" (p1, 5 children)\n- ex:section_4: \"## 2. Experimental\" (p2, 5 children) [deo:Methods]\n- ex:section_5: \"## 2.1. Nivolumab conjugation with DFO\" (p2, 5 children)\n- ex:section_6: \"## 2.2. Radiolabeling \n\n==================================================\n\nAbstract section content:\n[\n  {\n    \"iri\": \"ex:b_p001_0009\",\n    \"types\": [\n      \"doco:Paragraph\"\n    ],\n    \"text_preview\": \"Cancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify ca\",\n    \"page\": 1,\n    \"_section_title\": \"## A B S T R A C T\"\n  },\n  {\n    \"iri\": \"ex:b_p001_0010\",\n    \"types\": [\n      \"doco:Paragraph\"\n    ],\n    \"text_preview\": \"\\u00a9 2017 Elsevier Ltd. All rights reserved.\",\n    \"page\": 1\n  }\n]\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.787894+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 2, "reasoning": "Good start. I can see the document is about cancer immunotherapy and Nivolumab. Now I need to:\n1. Read the full abstract to understand the main findings\n2. Explore the experimental sections to find key measurements and entities\n3. Look for specific chemical entities (Nivolumab, DFO, radiolabels like Zr-89)\n4. Extract quantitative measurements (conjugation ratios, yields, etc.)\n\nLet me get the full text of the abstract paragraph and then search for key terms.", "code": "# Get full abstract text\nabstract_para = g_node_detail(\"ex:b_p001_0009\")\nprint(\"=== FULL ABSTRACT ===\")\nprint(abstract_para['properties'].get('kag:fullText', 'N/A'))\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Now let's search for key chemical entities\nprint(\"=== SEARCHING FOR KEY ENTITIES ===\\n\")\n\n# Search for Nivolumab\nnivo_results = g_search(\"Nivolumab\", limit=5)\nprint(f\"Nivolumab mentions: {len(nivo_results)}\")\nfor r in nivo_results[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:100]}...\")\n\nprint()\n\n# Search for DFO (desferrioxamine)\ndfo_results = g_search(\"DFO\", limit=5)\nprint(f\"DFO mentions: {len(dfo_results)}\")\nfor r in dfo_results[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:100]}...\")\n\nprint()\n\n# Search for Zirconium-89 or 89Zr\nzr_results = g_search(\"89Zr\", limit=5)\nprint(f\"89Zr mentions: {len(zr_results)}\")\nfor r in zr_results[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:100]}...\")", "output": "=== FULL ABSTRACT ===\nCancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify cancer cells and stimulate immune responses. The Programmed Death-1 (PD-1) protein is an immunoinhibitory receptor expressed by activated cytotoxic T-lymphocytes (CTL) that seek out and destroy cancer cells. Multiple cancer types express and upregulate the Programmed Death-Ligand 1 (PD-L1) and 2 (PD-L2) which bind to PD-1 as an immune escape mechanism. Nivolumab is a fully human ...<truncated>\n\n==================================================\n\n=== SEARCHING FOR KEY ENTITIES ===\n\nNivolumab mentions: 5\n  - ex:b_p001_0001: ...and preclinical PET evaluation of  \\( ^{89} \\) Zr-nivolumab (BMS-936558) in healthy non-human pri...\n  - ex:b_p001_0007: Keywords:\nNivolumab\nOpdivo\nPET\nZirconium-89\nPD-1\nPD-L1\nBMS-936558...\n  - ex:b_p001_0009: ...which bind to PD-1 as an immune escape mechanism. Nivolumab is a fully human IgG4 anti-PD-1 monoc...\n\nDFO mentions: 5\n  - ex:b_p002_0004: Desferrioxamine (DFO) is the most common chelator for  \\( {}^{89} \\) Zr-labeling, available commerci...\n  - ex:b_p002_0007: ## 2.1. Nivolumab conjugation with DFO...\n  - ex:b_p002_0008: ...rmation of a thiourea linkage to the bifunctional DFO chelator derivative, 1-(4-isothiocyanatophe...\n\n89Zr mentions: 0\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.787957+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 3, "reasoning": "Good progress! I can see this is a paper about radiolabeling Nivolumab (an anti-PD-1 antibody) with Zr-89 using DFO chelator. The search for \"89Zr\" returned 0 results, but I can see it mentioned in the snippets with special formatting. Let me:\n\n1. Search for \"Zirconium\" or \"Zr\" to find more mentions\n2. Explore the experimental sections to find key measurements (conjugation ratios, yields, specific activity, etc.)\n3. Look at the results sections to find claims about the imaging studies\n4. Start creating entities for the main chemicals and measurements\n\nLet me search more broadly and examine the experimental sections.", "code": "# Search for Zirconium more broadly\nprint(\"=== SEARCHING FOR ZIRCONIUM ===\\n\")\nzr_results = g_search(\"Zirconium\", limit=5)\nprint(f\"Zirconium mentions: {len(zr_results)}\")\nfor r in zr_results[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:150]}...\")\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Let's explore the experimental sections to find measurements\nprint(\"=== EXPERIMENTAL SECTIONS ===\\n\")\n\n# Section 2.1: Nivolumab conjugation with DFO\nsection_21 = g_section_content(\"ex:section_5\")\nprint(\"Section 2.1 - Nivolumab conjugation with DFO:\")\nfor item in section_21:\n    print(f\"  {item['iri']}: {item['text_preview'][:100]}...\")\n\nprint()\n\n# Section 2.2: Radiolabeling\nsection_22 = g_section_content(\"ex:section_6\")\nprint(\"Section 2.2 - Radiolabeling:\")\nfor item in section_22:\n    print(f\"  {item['iri']}: {item['text_preview'][:100]}...\")", "output": "=== SEARCHING FOR ZIRCONIUM ===\n\nZirconium mentions: 5\n  - ex:b_p001_0007: Keywords:\nNivolumab\nOpdivo\nPET\nZirconium-89\nPD-1\nPD-L1\nBMS-936558...\n  - ex:b_p008_0028: ...iometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858\u20132902....\n  - ex:b_p008_0030: 18. Zhang Y, Hong H, Cai W. PET tracers based on zirconium-89. Curr Radiopharm. 2011;4:131\u2013139....\n\n==================================================\n\n=== EXPERIMENTAL SECTIONS ===\n\nSection 2.1 - Nivolumab conjugation with DFO:\n  ex:b_p002_0008: Nivolumab was modified by formation of a thiourea linkage to the bifunctional DFO chelator derivativ...\n  ex:b_p002_0009: Nivolumab (10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentaacetic acid...\n  ex:b_p002_0010: The purity was determined by analytical SEC (10/300 GL Superdex 200, PBS buffer mobile phase) and pr...\n  ex:b_p002_0011: SPR experiments were performed to calculate the  \\( K_{D} \\)  for human PD-1 (hPD1(25\u2013167)-Myc-TVMV-...\n  ex:b_p002_0012: Response levels obtained for the primary mAb were approximately 3000 RU. Nivolumab and nivolumab-DFO...\n\nSection 2.2 - Radiolabeling:\n  ex:b_p002_0014: \\( ^{89} \\) Zr-oxalic acid was produced via the  \\( {}^{89} \\) Y(p,n) \\( ^{89} \\) Zr transmutation r...\n  ex:b_p003_0001: [image] page=3 bbox=[[90, 81, 470, 872]]...\n  ex:b_p003_0002: Scheme 1. Nivolumab conjugation to p-SCN-Bn-DFO and radiolabeling with  \\( ^{89} \\) Zr \\( ^{4+} \\) ....\n  ex:b_p003_0003: prepared from  \\( {}^{89} \\) Zr-oxalate and nivolumab-DFO following the procedures reported by Vosja...\n  ex:b_p003_0004: The reaction was transferred to a PD-10 column (GE Healthcare) previously equilibrated with PBS buff...\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788010+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 4, "reasoning": "Good progress! I can see this is a paper about:\n- Nivolumab (anti-PD-1 antibody) conjugated with DFO chelator\n- Radiolabeling with Zr-89 for PET imaging\n- Testing in non-human primates\n\nI need to extract:\n1. Chemical entities: Nivolumab, DFO (p-SCN-Bn-DFO), Zr-89, the conjugate\n2. Measurements: conjugation ratios, binding affinity (KD), radiochemical yield, specific activity\n3. Claims: about the imaging performance, biodistribution, etc.\n\nLet me now read the detailed experimental paragraphs to extract specific measurements and then look at the results sections for claims.", "code": "# Let's get detailed information from key experimental paragraphs\nprint(\"=== DETAILED EXPERIMENTAL DATA ===\\n\")\n\n# Get conjugation details\nconj_para = g_node_detail(\"ex:b_p002_0008\")\nprint(\"Conjugation paragraph:\")\nprint(conj_para['properties'].get('kag:fullText', 'N/A'))\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Get purity/characterization details\npurity_para = g_node_detail(\"ex:b_p002_0010\")\nprint(\"Purity/characterization paragraph:\")\nprint(purity_para['properties'].get('kag:fullText', 'N/A'))\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Get radiolabeling details\nradiolabel_para = g_node_detail(\"ex:b_p003_0003\")\nprint(\"Radiolabeling paragraph:\")\nprint(radiolabel_para['properties'].get('kag:fullText', 'N/A'))\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Search for specific measurements\nprint(\"=== SEARCHING FOR KEY MEASUREMENTS ===\\n\")\nyield_results = g_search(\"yield\", limit=5)\nprint(f\"Yield mentions: {len(yield_results)}\")\nfor r in yield_results[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:120]}...\")", "output": "=== DETAILED EXPERIMENTAL DATA ===\n\nConjugation paragraph:\nNivolumab was modified by formation of a thiourea linkage to the bifunctional DFO chelator derivative, 1-(4-isothiocyanatophenyl)-3-[6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaecisoanet]thiourea (p-SCN-Bn-DFO, Scheme. 1, step 1, Macrocyclics, B-705).\n\n==================================================\n\nPurity/characterization paragraph:\nThe purity was determined by analytical SEC (10/300 GL Superdex 200, PBS buffer mobile phase) and protein concentration by NanoDrop 2000c spectrophotometer. A CAR was calculated from the relative peak intensities in the deconvoluted LC/MS spectra of intact and/or reduced nivolumab-DFO.\n\n==================================================\n\nRadiolabeling paragraph:\nprepared from  \\( {}^{89} \\) Zr-oxalate and nivolumab-DFO following the procedures reported by Vosjan and co-workers with minor modifications (Scheme. 1, step 2). \\( ^{28} \\)  An average of 15 mCi of  \\( {}^{89} \\) Zr-oxalic acid in 300  \\( \\mu \\) L was neutralized with 300  \\( \\mu \\) L of 2 M Na \\( _{2} \\) CO \\( _{3} \\) . The volume was then diluted with 0.5 mL of 0.5 M HEPES buffer (pH 7.2). To this solution, nivolumab-DFO was added (0.5 mL of 1.5 mg/mL, 750  \\( \\mu \\) g) then an additional 0....<truncated>\n\n==================================================\n\n=== SEARCHING FOR KEY MEASUREMENTS ===\n\nYield mentions: 4\n  - ex:b_p004_0011: ...olumab-DFO was isolated after purification with a yield of 88% (8.8 mg, 0.44 mg/mL in PBS) from the parent mAb (10 mg...\n  - ex:b_p004_0014: \\( ^{89} \\) Zr-labeling yielded 225\u2013341 MBq of  \\( ^{89} \\) Zr-nivolumab with a moderate radiochemical yield of  \\( 53 \\...\n  - ex:b_p004_0018: \\( ^{b} \\)  Radiochemical yield, non-decay corrected....\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788058+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 5, "reasoning": "Good progress! I can see specific measurements emerging:\n- Conjugation yield: 88% (8.8 mg from 10 mg parent)\n- Radiochemical yield: 53% (moderate)\n- Activity: 225-341 MBq\n\nNow I need to:\n1. Continue extracting specific measurements (CAR, specific activity, KD values)\n2. Look at results sections for biodistribution data and imaging claims\n3. Start creating entities in G_entity for chemicals and measurements\n4. Create claims in G_claim for scientific findings\n\nLet me search for more specific measurements like CAR (chelator-to-antibody ratio), specific activity, and binding affinity data.", "code": "# Search for CAR (chelator-to-antibody ratio)\nprint(\"=== SEARCHING FOR CAR AND SPECIFIC ACTIVITY ===\\n\")\ncar_results = g_search(\"CAR\", limit=5)\nprint(f\"CAR mentions: {len(car_results)}\")\nfor r in car_results[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:120]}...\")\n\nprint()\n\n# Search for specific activity\nactivity_results = g_search(\"specific activity\", limit=5)\nprint(f\"Specific activity mentions: {len(activity_results)}\")\nfor r in activity_results[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:120]}...\")\n\nprint()\n\n# Search for KD or binding affinity\nkd_results = g_search(\"KD\", limit=5)\nprint(f\"KD mentions: {len(kd_results)}\")\nfor r in kd_results[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:120]}...\")\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Let's look at the results section to find key findings\nprint(\"=== EXPLORING RESULTS SECTIONS ===\\n\")\n# Search for sections with \"Results\" in the title\nresults_search = g_search(\"Results\", limit=10)\nprint(f\"Results mentions: {len(results_search)}\")\nfor r in results_search[:5]:\n    print(f\"  - {r['iri']} (p{r['page']}): {r['snippet'][:100]}...\")", "output": "=== SEARCHING FOR CAR AND SPECIFIC ACTIVITY ===\n\nCAR mentions: 5\n  - ex:b_p001_0012: The standard of care for many cancers includes combinations of chemotherapy, radiation, and surgical resection when ......\n  - ex:b_p002_0004: ...ant to determine the conjugate to antibody ratio (CAR) to minimize loss of biological activity from over modification...\n  - ex:b_p002_0009: ...sing a HiLoad 26/60 Superdex 200 column (GE Healthcare) and PBS buffer (150 mM NaCl, 200 mM NaPO \\( _{4} \\) , pH 7.2,...\n\nSpecific activity mentions: 5\n  - ex:b_p001_0009: ...tified by region of interest (ROI) analysis. Radioactivity in the spleen was significantly reduced by addition of exc...\n  - ex:b_p002_0004: ...tibody ratio (CAR) to minimize loss of biological activity from over modification. Site-specific DFO labeling of mAbs...\n  - ex:b_p003_0004: ...ly the first 1 mL fraction contained minimal radioactivity followed by a 1.5 mL fraction with the majority of purifie...\n\nKD mentions: 1\n  - ex:b_p005_0009: ...ed with gel filtration standard. UV Region 1: 670 kDa (18 min), Region 2: 158 kDa (26 min), Region 3: 44 kDa (31 min)...\n\n==================================================\n\n=== EXPLORING RESULTS SECTIONS ===\n\nResults mentions: 4\n  - ex:b_p001_0009 (p1): ...sues: lung, muscle, brain, heart, and kidney. The results indicate specific biodistribution to th...\n  - ex:b_p004_0009 (p4): ## 3. Results and discussion...\n  - ex:b_p005_0014 (p5): ...lthy NHPs. Despite a small number of animals, the results from this study show that splenic uptak...\n  - ex:b_p005_0015 (p5): ...s and other lymphocytes, which is consistent with results published by Wang and co-workers in NHP...\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788109+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 6, "reasoning": "Good progress! I've found key information about:\n- CAR (chelator-to-antibody ratio) - mentioned but need specific values\n- Specific activity - mentioned but need actual numbers\n- KD - only 1 mention, need to find binding affinity data\n- Results section starting at ex:b_p004_0009\n\nNow I need to:\n1. Read the full results section to extract specific numerical values\n2. Get the detailed paragraphs with CAR values, specific activity, and KD measurements\n3. Start creating entities and measurements in G_entity\n4. Extract claims from the results about biodistribution and imaging performance\n\nLet me get the detailed text from key paragraphs that likely contain the measurements.", "code": "# Get detailed results paragraphs\nprint(\"=== DETAILED RESULTS DATA ===\\n\")\n\n# Get the results section content\nresults_section = g_section_content(\"ex:section_9\")\nprint(\"Results section structure:\")\nfor item in results_section[:5]:\n    print(f\"  {item['iri']}: {item['text_preview'][:100]}...\")\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Get detailed yield paragraph\nyield_para = g_node_detail(\"ex:b_p004_0011\")\nprint(\"Yield details:\")\nprint(yield_para['properties'].get('kag:fullText', 'N/A'))\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Get radiolabeling yield paragraph\nradiolabel_yield = g_node_detail(\"ex:b_p004_0014\")\nprint(\"Radiolabeling yield details:\")\nprint(radiolabel_yield['properties'].get('kag:fullText', 'N/A'))\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Search for CAR value specifically\ncar_value_search = g_search(\"CAR of\", limit=5)\nprint(\"CAR value mentions:\")\nfor r in car_value_search[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:150]}...\")", "output": "=== DETAILED RESULTS DATA ===\n\nResults section structure:\n  ex:b_p004_0006: PET images (axial field of view of 7.6 cm) were acquired and scanners calibrated for  \\( {}^{89} \\) ...\n  ex:b_p004_0007: 54.5 \u00b1 11.0 MBq of  \\( {}^{89} \\) Zr-DFO-nivolumab was injected as a slow bolus over 20 min via ceph...\n  ex:b_p004_0008: MRI and PET images were manually co-registered using fiducial markers and anatomical information in ...\n\n==================================================\n\nYield details:\nPreparation of nivolumab-DFO in Scheme 1, step 1, was achieved through thiourea bond formation between the p-SCN-Bn-DFO chelator and lysine on the mAb. Nivolumab-DFO was isolated after purification with a yield of 88% (8.8 mg, 0.44 mg/mL in PBS) from the parent mAb (10 mg). Purity was determined to be  \\( >95\\% \\)  with a CAR of 1.14 (Fig. S3). The chelate ratio was determined by LC-MS versus isotope dilution assay. \\( ^{30-32} \\)  Future synthesis should lower the excess of the p-SCN-Bn-DFO che...<truncated>\n\n==================================================\n\nRadiolabeling yield details:\n\\( ^{89} \\) Zr-labeling yielded 225\u2013341 MBq of  \\( ^{89} \\) Zr-nivolumab with a moderate radiochemical yield of  \\( 53 \\pm 8\\% \\)  (non-decay-corrected). Both yields were recorded from the fraction used for imaging to optimize purity, thus resulting in a lower observed yields than the reaction produced. Purification of the tracer was done with PBS which could have hindered the yield due to interaction of the chloride ions resulting in radiolysis or phosphate chelating free  \\( ^{89} \\) Zr. \\( ^{...<truncated>\n\n==================================================\n\nCAR value mentions:\n  - ex:b_p001_0012: The standard of care for many cancers includes combinations of chemotherapy, radiation, and surgical resection wh......\n  - ex:b_p002_0004: ... widely used for in vivo imaging due to stability of the DFO- \\( Zr^{4+} \\)  complex, the commercial availability of DFO, and translational use in ...\n  - ex:b_", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788156+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 7, "reasoning": "Excellent! I've found key measurements:\n- CAR (chelator-to-antibody ratio): 1.14\n- Conjugation yield: 88% (8.8 mg from 10 mg)\n- Purity: >95%\n- Radiochemical yield: 53 \u00b1 8% (non-decay-corrected)\n- Activity: 225-341 MBq\n\nNow I need to:\n1. Search for specific activity values (MBq/mg or similar)\n2. Find KD (binding affinity) values from the SPR experiments mentioned earlier\n3. Look for biodistribution data and imaging results\n4. Start creating entities in G_entity for the main chemicals and measurements\n5. Create claims in G_claim for the scientific findings\n\nLet me search for specific activity and KD values, then start building the entity graph.", "code": "# Search for specific activity values\nprint(\"=== SEARCHING FOR SPECIFIC ACTIVITY VALUES ===\\n\")\nmci_results = g_search(\"mCi\", limit=5)\nprint(f\"mCi mentions: {len(mci_results)}\")\nfor r in mci_results[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:150]}...\")\n\nprint()\n\nmbq_results = g_search(\"MBq\", limit=5)\nprint(f\"MBq mentions: {len(mbq_results)}\")\nfor r in mbq_results[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:150]}...\")\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Get the SPR paragraph with KD values\nprint(\"=== BINDING AFFINITY DATA ===\\n\")\nspr_para = g_node_detail(\"ex:b_p002_0011\")\nprint(\"SPR/KD paragraph:\")\nprint(spr_para['properties'].get('kag:fullText', 'N/A'))\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Get the next SPR paragraph\nspr_para2 = g_node_detail(\"ex:b_p002_0012\")\nprint(\"SPR results paragraph:\")\nprint(spr_para2['properties'].get('kag:fullText', 'N/A'))", "output": "=== SEARCHING FOR SPECIFIC ACTIVITY VALUES ===\n\nmCi mentions: 1\n  - ex:b_p003_0003: ...Scheme. 1, step 2). \\( ^{28} \\)  An average of 15 mCi of  \\( {}^{89} \\) Zr-oxalic acid in 300  \\( \\mu \\) L was neutralized with 300  \\( \\mu \\) L of...\n\nMBq mentions: 4\n  - ex:b_p004_0007: 54.5 \u00b1 11.0 MBq of  \\( {}^{89} \\) Zr-DFO-nivolumab was injected as a slow bolus over 20 min via cephalic vein in......\n  - ex:b_p004_0014: \\( ^{89} \\) Zr-labeling yielded 225\u2013341 MBq of  \\( ^{89} \\) Zr-nivolumab with a moderate radiochemical yield of  \\( 53 \\pm 8\\% \\)  (non-deca......\n  - ex:b_p005_0010: ... activity was calculated to be  \\( 352 \\pm 87 \\)  MBq/mg, see Table 1 for individual reaction data. Analysis by SEC determined the samples had good...\n\n==================================================\n\n=== BINDING AFFINITY DATA ===\n\nSPR/KD paragraph:\nSPR experiments were performed to calculate the  \\( K_{D} \\)  for human PD-1 (hPD1(25\u2013167)-Myc-TVMV-His, Bristol-Myers Squibb) to nivolumab and nivolumab-DFO. \\( ^{27} \\)  Each study was done at 25 \u00b0C using a ProteOn XPR36 instrument with a running buffer of PBS with 0.05% Tween (TEKNOVA, P1192), that is held constant throughout the experiment. An anti-human IgG mAb was directly immobilized via amine coupling on a GLC sensor chip. The chip surface was then activated with a 1:1 mixture of 40 mM N...<truncated>\n\n==================================================\n\nSPR results paragraph:\nResponse levels obtained for the primary mAb were approximately 3000 RU. Nivolumab and nivolumab-DFO were captured on the surface by the anti-human IgG to a response level of approximately 550 RU. Five concentrations of hPD-1 (from 40 nM to 2.5 nM, with a 2-fold serial dilution in the running buffer) were injected at 30  \\( \\mu \\) L/min for 3 min and the dissociation was monitored for 10 min. Surfaces were regenerated with two injections of 0.85%  \\( H_{3}PO_{4} \\)  (100  \\( \\mu \\) L/min for 18 ...<truncated>\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788202+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 8, "reasoning": "Great! I found the specific activity value: 352 \u00b1 87 MBq/mg. Now I need to:\n1. Find the actual KD values from the SPR experiments\n2. Search for biodistribution data and imaging results\n3. Start creating entities in G_entity for chemicals and measurements\n4. Create claims in G_claim for scientific findings\n\nLet me search for the KD values and biodistribution data, then start building the entity graph systematically.", "code": "# Search for KD values\nprint(\"=== SEARCHING FOR KD VALUES ===\\n\")\nkd_value_search = g_search(\"nM\", limit=10)\nprint(f\"nM (nanomolar) mentions: {len(kd_value_search)}\")\nfor r in kd_value_search[:5]:\n    print(f\"  - {r['iri']}: {r['snippet'][:150]}...\")\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Search for biodistribution data\nprint(\"=== BIODISTRIBUTION DATA ===\\n\")\nbiodist_search = g_search(\"biodistribution\", limit=5)\nprint(f\"Biodistribution mentions: {len(biodist_search)}\")\nfor r in biodist_search[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:150]}...\")\n\nprint()\n\n# Search for uptake data\nuptake_search = g_search(\"uptake\", limit=5)\nprint(f\"Uptake mentions: {len(uptake_search)}\")\nfor r in uptake_search[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:150]}...\")\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Look for Table 1 which was mentioned for reaction data\nprint(\"=== SEARCHING FOR TABLES ===\\n\")\ntable_search = g_search(\"Table 1\", limit=5)\nprint(f\"Table 1 mentions: {len(table_search)}\")\nfor r in table_search[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:150]}...\")", "output": "=== SEARCHING FOR KD VALUES ===\n\nnM (nanomolar) mentions: 3\n  - ex:b_p002_0012: ...ely 550 RU. Five concentrations of hPD-1 (from 40 nM to 2.5 nM, with a 2-fold serial dilution in the running buffer) were injected at 30  \\( \\mu \\)...\n  - ex:b_p003_0007: ...em transfer and to provide precise anatomical alignment. If necessary, ventilator tidal volume was utilized at 10\u201320 mL/kg for the procedure to mai...\n  - ex:b_p004_0012: ...to hPD-1 are similar with a  \\( K_{D} \\)  of 3.10 nM for nivolumab and 3.75 nM for nivolumab-DFO (Fig. S4). These are comparable to binding of nivo...\n\n==================================================\n\n=== BIODISTRIBUTION DATA ===\n\nBiodistribution mentions: 5\n  - ex:b_p001_0009: ...on-human primates (NHP) as a preliminary study of biodistribution and clearance. The radiochemical and in vivo stabilities of the  \\( ^{89} \\) Zr c...\n  - ex:b_p002_0003: ...use pharmacokinetics can require days for optimal biodistribution. \\( ^{17,18} \\)  Given that nivolumab has a dose-dependent half-life of 5 (1 mg/k...\n  - ex:b_p004_0008: ...Data Examiner (AMIDE). \\( ^{29} \\)  Image-derived biodistribution over the course of the imaging study (up to 8 days post injection, p.i.) were mea...\n\nUptake mentions: 5\n  - ex:b_p001_0009: ...s following injection. Image-derived standardized uptake values (SUV) were quantified by region of interest (ROI) analysis. Radioactivity in the sp...\n  - ex:b_p002_0003: ... {}^{124} \\) I suffers limitations due to thyroid uptake following in vivo dehalogenation as well as decreased resolution. \\( ^{15} \\)  Chelator ba...\n  - ex:b_p004_0008: ...st injection, p.i.) were measured as standardized uptake values (SUVs) in the identified regions for all imaging data sets....\n\n==================================================\n\n=== SEARCHING FOR TABLES ===\n\nTable 1 mentions: 5\n  - ex:b_p001_0009: ... stimulate immune responses. The Programmed Death-1 (PD-1) protein is an immunoinhibitory receptor expressed by activated cytotoxic T-lymphoc", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788241+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 9, "reasoning": "Excellent progress! I've found the KD values:\n- Nivolumab: KD = 3.10 nM\n- Nivolumab-DFO: KD = 3.75 nM\n\nI also found Table 1 which contains injected dose data. Now I have enough information to start creating entities and measurements in G_entity. Let me:\n\n1. First, get the full Table 1 data to see the injected doses\n2. Get more biodistribution/uptake results\n3. Then systematically create entities for:\n   - Chemical entities (Nivolumab, DFO, p-SCN-Bn-DFO, Zr-89, Nivolumab-DFO conjugate, Zr-89-Nivolumab)\n   - Measurements (CAR, yields, specific activity, KD values, injected doses, SUV values)\n4. Create claims about the findings\n\nLet me get Table 1 details and more results data first.", "code": "# Get Table 1 details\nprint(\"=== TABLE 1 DATA ===\\n\")\ntable1_para = g_node_detail(\"ex:b_p004_0015\")\nprint(\"Table 1:\")\nprint(table1_para['properties'].get('kag:fullText', 'N/A'))\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Get the KD results paragraph in full\nkd_para = g_node_detail(\"ex:b_p004_0012\")\nprint(\"KD results paragraph:\")\nprint(kd_para['properties'].get('kag:fullText', 'N/A'))\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Get specific activity paragraph\nspec_act_para = g_node_detail(\"ex:b_p005_0010\")\nprint(\"Specific activity paragraph:\")\nprint(spec_act_para['properties'].get('kag:fullText', 'N/A'))\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Search for SUV values and biodistribution results\nprint(\"=== SUV AND BIODISTRIBUTION RESULTS ===\\n\")\nsuv_search = g_search(\"SUV\", limit=5)\nprint(f\"SUV mentions: {len(suv_search)}\")\nfor r in suv_search[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:150]}...\")", "output": "=== TABLE 1 DATA ===\n\nTable 1:\nTable 1\n\nInjected Doses of  \\( ^{89} \\) Zr-Nivolumab for Tracer only and Carrier-Added Studies in NHPs.\n\n==================================================\n\nKD results paragraph:\nThe  \\( K_{D} \\)  values for nivolumab and nivolumab-DFO binding to hPD-1 are similar with a  \\( K_{D} \\)  of 3.10 nM for nivolumab and 3.75 nM for nivolumab-DFO (Fig. S4). These are comparable to binding of nivolumab to cynoPD-1 with a  \\( K_{D} \\)  of 3.92 nM. \\( ^{19} \\)  Nivolumab-DFO was stored in single use vials (1 mL of 1.5 mg/mL) at  \\( -78^{\\circ}C \\)  and allowed to warm to room temperature prior to conjugation with  \\( {}^{89}Zr \\) . The purity after one freeze thaw cycle was unchang...<truncated>\n\n==================================================\n\nSpecific activity paragraph:\npurification conditions in future studies to isolate more  \\( {}^{89} \\) Zr-nivolumab with 0.25 M sodium acetate buffer as an alternative to PBS. Protein concentration was determined by NanoDrop and specific activity was calculated to be  \\( 352 \\pm 87 \\)  MBq/mg, see Table 1 for individual reaction data. Analysis by SEC determined the samples had good purity of >87% with the only detectable impurity being a single peak for a higher molecular weight species (HMWs) most likely an aggregate. The n...<truncated>\n\n==================================================\n\n=== SUV AND BIODISTRIBUTION RESULTS ===\n\nSUV mentions: 5\n  - ex:b_p001_0009: ...ection. Image-derived standardized uptake values (SUV) were quantified by region of interest (ROI) analysis. Radioactivity in the spleen was signif...\n  - ex:b_p004_0008: ....i.) were measured as standardized uptake values (SUVs) in the identified regions for all imaging data sets....\n  - ex:b_p007_0004: Fig. 3. Image-derived biodistribution in NHPs (SUV): a Tracer only NHP. b Carrier-added 1 mg/kg nivolumab NHP. c Carrier-added 3 mg/kg nivolumab NH......\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788277+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 10, "reasoning": "I've gathered substantial information about the paper. Now I need to:\n\n1. Get more detailed biodistribution/SUV data from the results\n2. Start systematically creating entities in G_entity for:\n   - Chemical entities (Nivolumab, DFO, p-SCN-Bn-DFO, Zr-89, conjugates)\n   - Measurements (CAR, yields, KD, specific activity, doses, SUV values)\n3. Create claims in G_claim for scientific findings\n4. Ground entities to specific document locations\n\nLet me first explore the biodistribution results in more detail, then start building the entity graph. I'll look at Figure 3 which shows SUV data and get more specific results about organ uptake.", "code": "# Get biodistribution results paragraphs\nprint(\"=== DETAILED BIODISTRIBUTION RESULTS ===\\n\")\n\n# Search for spleen data (mentioned in abstract as significant)\nspleen_search = g_search(\"spleen\", limit=5)\nprint(f\"Spleen mentions: {len(spleen_search)}\")\nfor r in spleen_search[:3]:\n    print(f\"  - {r['iri']}: {r['snippet'][:150]}...\")\n\nprint()\n\n# Get Figure 3 information\nfig3_info = g_figure_info(\"ex:b_p007_0004\")\nprint(\"\\nFigure 3 details:\")\nprint(json.dumps(fig3_info, indent=2))\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Search for specific organ uptake data\nprint(\"=== ORGAN UPTAKE DATA ===\\n\")\nliver_search = g_search(\"liver\", limit=3)\nprint(f\"Liver mentions: {len(liver_search)}\")\nfor r in liver_search[:2]:\n    print(f\"  - {r['iri']}: {r['snippet'][:120]}...\")\n\nprint()\n\nkidney_search = g_search(\"kidney\", limit=3)\nprint(f\"Kidney mentions: {len(kidney_search)}\")\nfor r in kidney_search[:2]:\n    print(f\"  - {r['iri']}: {r['snippet'][:120]}...\")", "output": "=== DETAILED BIODISTRIBUTION RESULTS ===\n\nSpleen mentions: 5\n  - ex:b_p001_0009: ... of interest (ROI) analysis. Radioactivity in the spleen was significantly reduced by addition of excess nivolumab compared to the tracer only stud...\n  - ex:b_p004_0008: ...d PET images (Fig. S6). The brain, thymus, heart, spleen, kidney, lung, liver, stomach wall, spine, and background area (e.g. muscle) were selected...\n  - ex:b_p005_0013: ...ealed that distribution of radioactivity into the spleen was reduced by the addition of unlabeled nivolumab compared to tracer only studies at all ...\n\n\nFigure 3 details:\n{\n  \"error\": \"Not a doco:Figure: ex:b_p007_0004\"\n}\n\n==================================================\n\n=== ORGAN UPTAKE DATA ===\n\nLiver mentions: 3\n  - ex:b_p001_0009: ...the tracer only study at all imaging time points. Liver uptake of the radiotracer was consistent as a clearance organ...\n  - ex:b_p002_0014: ...rth America, Inc. (Richmond, VA) with overnight delivery to Bristol-Myers Squibb (Princeton, NJ). The  \\( {}^{89} \\) ...\n\nKidney mentions: 2\n  - ex:b_p001_0009: ...om other tissues: lung, muscle, brain, heart, and kidney. The results indicate specific biodistribution to the spleen...\n  - ex:b_p004_0008: ...ages (Fig. S6). The brain, thymus, heart, spleen, kidney, lung, liver, stomach wall, spine, and background area (e.g....\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788310+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 11, "reasoning": "I have gathered substantial information about the paper. Now I need to start creating entities and measurements in G_entity, and claims in G_claim. Let me:\n\n1. First, get more specific biodistribution results with actual SUV values\n2. Then systematically create entities for:\n   - Chemical entities (Nivolumab, DFO, p-SCN-Bn-DFO, Zr-89, conjugates)\n   - Measurements (CAR, yields, KD, specific activity, doses, SUV values)\n3. Create claims about the scientific findings\n4. Ground all entities to specific document locations\n\nLet me search for the actual figure with biodistribution data and get specific SUV values from the results paragraphs.", "code": "# Search for figures\nprint(\"=== SEARCHING FOR FIGURES ===\\n\")\nfig_search = g_search(\"Fig\", limit=10)\nprint(f\"Figure mentions: {len(fig_search)}\")\nfor r in fig_search[:5]:\n    print(f\"  - {r['iri']}: {r['snippet'][:120]}...\")\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Get detailed biodistribution results paragraph\nprint(\"=== BIODISTRIBUTION RESULTS PARAGRAPHS ===\\n\")\nbiodist_para = g_node_detail(\"ex:b_p005_0013\")\nprint(\"Spleen biodistribution paragraph:\")\nprint(biodist_para['properties'].get('kag:fullText', 'N/A'))\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Get liver uptake paragraph\nliver_para = g_node_detail(\"ex:b_p001_0009\")\nprint(\"Abstract biodistribution summary:\")\nprint(liver_para['properties'].get('kag:fullText', 'N/A')[:500])\n\nprint(\"\\n\" + \"=\"*50 + \"\\n\")\n\n# Now let's start creating entities - begin with the main chemical entities\nprint(\"=== STARTING ENTITY CREATION ===\\n\")\nprint(\"I will now create entities for the key chemicals and measurements found in this paper.\")", "output": "=== SEARCHING FOR FIGURES ===\n\nFigure mentions: 9\n  - ex:b_p004_0008: ...ges, and applied to the co-registered PET images (Fig. S6). The brain, thymus, heart, spleen, kidney, lung, liver, st...\n  - ex:b_p004_0011: ...etermined to be  \\( >95\\% \\)  with a CAR of 1.14 (Fig. S3). The chelate ratio was determined by LC-MS versus isotope ...\n  - ex:b_p004_0012: ...0 nM for nivolumab and 3.75 nM for nivolumab-DFO (Fig. S4). These are comparable to binding of nivolumab to cynoPD-1 ...\n  - ex:b_p005_0009: Fig. 1. SEC profiles of  \\( {}^{89} \\) Zr-nivolumab in radioactive counts and UV absorbance. a  \\( {......\n  - ex:b_p005_0010: ... filtration standard and nivolumab-DFO precursor, Fig. 1....\n\n==================================================\n\n=== BIODISTRIBUTION RESULTS PARAGRAPHS ===\n\nSpleen biodistribution paragraph:\nPET derived images of NHPs (Fig. 3), revealed that distribution of radioactivity into the spleen was reduced by the addition of unlabeled nivolumab compared to tracer only studies at all imaging time points ( \\( -82.5 \\pm 4.6\\% \\) ; range:  \\( -75.2 \\)  to  \\( -87.0\\% \\) , Table 2). Due to the small number of test animals, statistical data could not be provided. The PK for the two pre-dosed NHPs are reported in Table 3. In the PK analysis, the concentration of nivolumab in carrier-added of 1 mg/...<truncated>\n\n==================================================\n\nAbstract biodistribution summary:\nCancer immunotherapy, unlike traditional cytotoxic chemotherapeutic treatments, engages the immune system to identify cancer cells and stimulate immune responses. The Programmed Death-1 (PD-1) protein is an immunoinhibitory receptor expressed by activated cytotoxic T-lymphocytes (CTL) that seek out and destroy cancer cells. Multiple cancer types express and upregulate the Programmed Death-Ligand 1 (PD-L1) and 2 (PD-L2) which bind to PD-1 as an immune escape mechanism. Nivolumab is a fully human \n\n==================================================\n\n=== STARTING ENTITY ", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788350+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 12, "reasoning": "I have gathered comprehensive information about this paper on Zr-89 labeled Nivolumab for PET imaging. Now I need to systematically create entities in G_entity and claims in G_claim. \n\nKey entities to create:\n1. Chemical entities: Nivolumab, DFO (p-SCN-Bn-DFO), Zr-89, Nivolumab-DFO conjugate, Zr-89-Nivolumab\n2. Measurements: CAR (1.14), conjugation yield (88%), radiochemical yield (53\u00b18%), specific activity (352\u00b187 MBq/mg), KD values (3.10 nM for Nivolumab, 3.75 nM for Nivolumab-DFO)\n3. Biological targets: PD-1, PD-L1, PD-L2\n4. Claims: about biodistribution, spleen uptake reduction, imaging performance\n\nI'll start by creating the main chemical entities with proper SIO/QUDT classes, then add measurements, then create claims. I'll ground each entity to specific document locations.", "code": "# Start creating chemical entities in G_entity graph\n\nprint(\"=== CREATING CHEMICAL ENTITIES ===\\n\")\n\n# 1. Create Nivolumab entity\nnivolumab = op_create_entity(\n    entity_id=\"nivolumab_01\",\n    class_iri=\"sio:ChemicalEntity\",\n    graph=\"entity\"\n)\nprint(f\"Created Nivolumab: {nivolumab}\")\n\n# Add type as antibody/protein\nop_assert_type(\"ex:nivolumab_01\", \"sio:Protein\", graph=\"entity\")\n\n# Set label\nop_set_literal(\"ex:nivolumab_01\", \"rdfs:label\", \"Nivolumab\", datatype_iri=None, graph=\"entity\")\n\n# Set description\nop_set_literal(\"ex:nivolumab_01\", \"rdfs:comment\", \n               \"Fully human IgG4 anti-PD-1 monoclonal antibody\", \n               datatype_iri=None, graph=\"entity\")\n\n# Ground to document - abstract paragraph\nop_add_link(\"ex:nivolumab_01\", \"prov:wasDerivedFrom\", \"ex:b_p001_0009\", graph=\"entity\")\n\nprint()\n\n# 2. Create DFO chelator entity\ndfo = op_create_entity(\n    entity_id=\"dfo_chelator_01\",\n    class_iri=\"sio:ChemicalEntity\",\n    graph=\"entity\"\n)\nprint(f\"Created DFO: {dfo}\")\n\nop_set_literal(\"ex:dfo_chelator_01\", \"rdfs:label\", \"p-SCN-Bn-DFO\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:dfo_chelator_01\", \"rdfs:comment\",\n               \"1-(4-isothiocyanatophenyl)-3-[6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaecisoanet]thiourea\",\n               datatype_iri=None, graph=\"entity\")\n\n# Ground to conjugation paragraph\nop_add_link(\"ex:dfo_chelator_01\", \"prov:wasDerivedFrom\", \"ex:b_p002_0008\", graph=\"entity\")\n\nprint()\n\n# 3. Create Zr-89 radioisotope entity\nzr89 = op_create_entity(\n    entity_id=\"zr89_01\",\n    class_iri=\"sio:ChemicalEntity\",\n    graph=\"entity\"\n)\nprint(f\"Created Zr-89: {zr89}\")\n\nop_assert_type(\"ex:zr89_01\", \"sio:Atom\", graph=\"entity\")\n\nop_set_literal(\"ex:zr89_01\", \"rdfs:label\", \"Zirconium-89\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:zr89_01\", \"rdfs:comment\", \"Radioisotope for PET imaging\", datatype_iri=None, graph=\"entity\")\n\n# Ground to radiolabeling paragraph\nop_add_link(\"ex:zr89_01\", \"prov:wasDerivedFrom\", \"ex:b_p003_0003\", graph=\"entity\")\n\nprint()\n\n# 4. Create Nivolumab-DFO conjugate entity\nnivo_dfo = op_create_entity(\n    entity_id=\"nivolumab_dfo_01\",\n    class_iri=\"sio:ChemicalEntity\",\n    graph=\"entity\"\n)\nprint(f\"Created Nivolumab-DFO: {nivo_dfo}\")\n\nop_set_literal(\"ex:nivolumab_dfo_01\", \"rdfs:label\", \"Nivolumab-DFO conjugate\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:nivolumab_dfo_01\", \"rdfs:comment\",\n               \"Nivolumab conjugated with p-SCN-Bn-DFO via thiourea linkage\",\n               datatype_iri=None, graph=\"entity\")\n\n# Ground to results paragraph\nop_add_link(\"ex:nivolumab_dfo_01\", \"prov:wasDerivedFrom\", \"ex:b_p004_0011\", graph=\"entity\")\n\n# Link to parent entities\nop_add_link(\"ex:nivolumab_dfo_01\", \"sio:has-component-part\", \"ex:nivolumab_01\", graph=\"entity\")\nop_add_link(\"ex:nivolumab_dfo_01\", \"sio:has-component-part\", \"ex:dfo_chelator_01\", graph=\"entity\")\n\nprint()\n\n# 5. Create Zr-89-Nivolumab final tracer entity\nzr89_nivo = op_create_entity(\n    entity_id=\"zr89_nivolumab_01\",\n    class_iri=\"sio:ChemicalEntity\",\n    graph=\"entity\"\n)\nprint(f\"Created Zr-89-Nivolumab: {zr89_nivo}\")\n\nop_set_literal(\"ex:zr89_nivolumab_01\", \"rdfs:label\", \"89Zr-Nivolumab\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:zr89_nivolumab_01\", \"rdfs:comment\",\n               \"Zirconium-89 labeled Nivolumab PET tracer\",\n               datatype_iri=None, graph=\"entity\")\n\n# Ground to radiolabeling results\nop_add_link(\"ex:zr89_nivolumab_01\", \"prov:wasDerivedFrom\", \"ex:b_p004_0014\", graph=\"entity\")\n\n# Link to parent entities\nop_add_link(\"ex:zr89_nivolumab_01\", \"sio:has-component-part\", \"ex:nivolumab_dfo_01\", graph=\"entity\")\nop_add_link(\"ex:zr89_nivolumab_01\", \"sio:has-component-part\", \"ex:zr89_01\", graph=\"entity\")\n\nprint(\"\\n=== CHEMICAL ENTITIES CREATED ===\")", "output": "=== CREATING CHEMICAL ENTITIES ===\n\nCreated Nivolumab: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/nivolumab_01', 'class': 'http://semanticscience.org/resource/ChemicalEntity', 'graph': 'entity'}\n\nCreated DFO: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/dfo_chelator_01', 'class': 'http://semanticscience.org/resource/ChemicalEntity', 'graph': 'entity'}\n\nCreated Zr-89: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/zr89_01', 'class': 'http://semanticscience.org/resource/ChemicalEntity', 'graph': 'entity'}\n\nCreated Nivolumab-DFO: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/nivolumab_dfo_01', 'class': 'http://semanticscience.org/resource/ChemicalEntity', 'graph': 'entity'}\n\nCreated Zr-89-Nivolumab: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/zr89_nivolumab_01', 'class': 'http://semanticscience.org/resource/ChemicalEntity', 'graph': 'entity'}\n\n=== CHEMICAL ENTITIES CREATED ===\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788390+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 13, "reasoning": "Good progress! I've created the main chemical entities. Now I need to:\n\n1. Create biological target entities (PD-1, PD-L1, PD-L2)\n2. Create measurement entities for:\n   - CAR (chelator-to-antibody ratio): 1.14\n   - Conjugation yield: 88%\n   - Purity: >95%\n   - Radiochemical yield: 53 \u00b1 8%\n   - Specific activity: 352 \u00b1 87 MBq/mg\n   - KD values: 3.10 nM (Nivolumab), 3.75 nM (Nivolumab-DFO)\n3. Create claims about the scientific findings (biodistribution, imaging performance)\n4. Validate the graphs\n\nLet me continue by creating the biological target entities and then the measurement entities.", "code": "# Create biological target entities\n\nprint(\"=== CREATING BIOLOGICAL TARGET ENTITIES ===\\n\")\n\n# 1. Create PD-1 entity\npd1 = op_create_entity(\n    entity_id=\"pd1_protein_01\",\n    class_iri=\"sio:Protein\",\n    graph=\"entity\"\n)\nprint(f\"Created PD-1: {pd1}\")\n\nop_set_literal(\"ex:pd1_protein_01\", \"rdfs:label\", \"PD-1\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:pd1_protein_01\", \"rdfs:comment\",\n               \"Programmed Death-1 protein, immunoinhibitory receptor expressed by activated cytotoxic T-lymphocytes\",\n               datatype_iri=None, graph=\"entity\")\n\n# Ground to abstract\nop_add_link(\"ex:pd1_protein_01\", \"prov:wasDerivedFrom\", \"ex:b_p001_0009\", graph=\"entity\")\n\n# Link Nivolumab as binding to PD-1\nop_add_link(\"ex:nivolumab_01\", \"sio:has-target\", \"ex:pd1_protein_01\", graph=\"entity\")\n\nprint()\n\n# 2. Create PD-L1 entity\npdl1 = op_create_entity(\n    entity_id=\"pdl1_protein_01\",\n    class_iri=\"sio:Protein\",\n    graph=\"entity\"\n)\nprint(f\"Created PD-L1: {pdl1}\")\n\nop_set_literal(\"ex:pdl1_protein_01\", \"rdfs:label\", \"PD-L1\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:pdl1_protein_01\", \"rdfs:comment\",\n               \"Programmed Death-Ligand 1, binds to PD-1 as immune escape mechanism\",\n               datatype_iri=None, graph=\"entity\")\n\nop_add_link(\"ex:pdl1_protein_01\", \"prov:wasDerivedFrom\", \"ex:b_p001_0009\", graph=\"entity\")\n\nprint()\n\n# 3. Create PD-L2 entity\npdl2 = op_create_entity(\n    entity_id=\"pdl2_protein_01\",\n    class_iri=\"sio:Protein\",\n    graph=\"entity\"\n)\nprint(f\"Created PD-L2: {pdl2}\")\n\nop_set_literal(\"ex:pdl2_protein_01\", \"rdfs:label\", \"PD-L2\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:pdl2_protein_01\", \"rdfs:comment\",\n               \"Programmed Death-Ligand 2, binds to PD-1 as immune escape mechanism\",\n               datatype_iri=None, graph=\"entity\")\n\nop_add_link(\"ex:pdl2_protein_01\", \"prov:wasDerivedFrom\", \"ex:b_p001_0009\", graph=\"entity\")\n\nprint(\"\\n=== BIOLOGICAL TARGET ENTITIES CREATED ===\\n\")\n\n# Now create measurement entities\nprint(\"=== CREATING MEASUREMENT ENTITIES ===\\n\")\n\n# 1. CAR (Chelator-to-Antibody Ratio) measurement\ncar_measurement = op_create_entity(\n    entity_id=\"car_measurement_01\",\n    class_iri=\"qudt:QuantityValue\",\n    graph=\"entity\"\n)\nprint(f\"Created CAR measurement: {car_measurement}\")\n\nop_set_literal(\"ex:car_measurement_01\", \"rdfs:label\", \"CAR of Nivolumab-DFO\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:car_measurement_01\", \"qudt:numericValue\", \"1.14\", datatype_iri=\"xsd:double\", graph=\"entity\")\n\nop_set_literal(\"ex:car_measurement_01\", \"rdfs:comment\",\n               \"Chelator-to-antibody ratio determined by LC-MS\",\n               datatype_iri=None, graph=\"entity\")\n\n# Link to the conjugate entity\nop_add_link(\"ex:nivolumab_dfo_01\", \"sio:has-measurement-value\", \"ex:car_measurement_01\", graph=\"entity\")\n\n# Ground to results paragraph\nop_add_link(\"ex:car_measurement_01\", \"prov:wasDerivedFrom\", \"ex:b_p004_0011\", graph=\"entity\")\n\nprint()\n\n# 2. Conjugation yield measurement\nconj_yield = op_create_entity(\n    entity_id=\"conjugation_yield_01\",\n    class_iri=\"qudt:QuantityValue\",\n    graph=\"entity\"\n)\nprint(f\"Created conjugation yield: {conj_yield}\")\n\nop_set_literal(\"ex:conjugation_yield_01\", \"rdfs:label\", \"Conjugation yield\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:conjugation_yield_01\", \"qudt:numericValue\", \"88\", datatype_iri=\"xsd:double\", graph=\"entity\")\n\nop_set_literal(\"ex:conjugation_yield_01\", \"qudt:unit\", \"percent\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:conjugation_yield_01\", \"rdfs:comment\",\n               \"Yield of Nivolumab-DFO after purification (8.8 mg from 10 mg parent)\",\n               datatype_iri=None, graph=\"entity\")\n\nop_add_link(\"ex:nivolumab_dfo_01\", \"sio:has-measurement-value\", \"ex:conjugation_yield_01\", graph=\"entity\")\n\nop_add_link(\"ex:conjugation_yield_01\", \"prov:wasDerivedFrom\", \"ex:b_p004_0011\", graph=\"entity\")\n\nprint()\n\n# 3. Purity measurement\npurity = op_create_entity(\n    entity_id=\"purity_measurement_01\",\n    c", "output": "=== CREATING BIOLOGICAL TARGET ENTITIES ===\n\nCreated PD-1: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/pd1_protein_01', 'class': 'http://semanticscience.org/resource/Protein', 'graph': 'entity'}\n\nCreated PD-L1: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/pdl1_protein_01', 'class': 'http://semanticscience.org/resource/Protein', 'graph': 'entity'}\n\nCreated PD-L2: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/pdl2_protein_01', 'class': 'http://semanticscience.org/resource/Protein', 'graph': 'entity'}\n\n=== BIOLOGICAL TARGET ENTITIES CREATED ===\n\n=== CREATING MEASUREMENT ENTITIES ===\n\nCreated CAR measurement: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/car_measurement_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}\n\nCreated conjugation yield: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/conjugation_yield_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}\n\nCreated purity measurement: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/purity_measurement_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}\n\nCreated radiochemical yield: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/radiochemical_yield_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}\n\nCreated specific activity: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/specific_activity_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}\n\n=== MEASUREMENT ENTITIES CREATED ===\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788479+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 14, "reasoning": "Good progress! I've created the main chemical entities, biological targets, and several key measurements. Now I need to:\n\n1. Create KD (binding affinity) measurements for Nivolumab and Nivolumab-DFO binding to PD-1\n2. Create activity/dose measurements (225-341 MBq, 54.5 \u00b1 11.0 MBq injected dose)\n3. Create claims in G_claim about:\n   - The biodistribution findings (spleen uptake reduction)\n   - The imaging performance\n   - The binding affinity preservation after conjugation\n4. Validate the graphs to ensure SHACL conformance\n5. Finalize and submit\n\nLet me continue by creating the KD measurements and then move to creating claims in the G_claim graph.", "code": "# Create KD (binding affinity) measurements\n\nprint(\"=== CREATING BINDING AFFINITY MEASUREMENTS ===\\n\")\n\n# 1. KD for Nivolumab binding to PD-1\nkd_nivo = op_create_entity(\n    entity_id=\"kd_nivolumab_01\",\n    class_iri=\"qudt:QuantityValue\",\n    graph=\"entity\"\n)\nprint(f\"Created KD Nivolumab: {kd_nivo}\")\n\nop_set_literal(\"ex:kd_nivolumab_01\", \"rdfs:label\", \"KD of Nivolumab to PD-1\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:kd_nivolumab_01\", \"qudt:numericValue\", \"3.10\", datatype_iri=\"xsd:double\", graph=\"entity\")\n\nop_set_literal(\"ex:kd_nivolumab_01\", \"qudt:unit\", \"nM\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:kd_nivolumab_01\", \"rdfs:comment\",\n               \"Dissociation constant for Nivolumab binding to human PD-1, measured by SPR\",\n               datatype_iri=None, graph=\"entity\")\n\n# Link to Nivolumab entity\nop_add_link(\"ex:nivolumab_01\", \"sio:has-measurement-value\", \"ex:kd_nivolumab_01\", graph=\"entity\")\n\n# Ground to KD results paragraph\nop_add_link(\"ex:kd_nivolumab_01\", \"prov:wasDerivedFrom\", \"ex:b_p004_0012\", graph=\"entity\")\n\nprint()\n\n# 2. KD for Nivolumab-DFO binding to PD-1\nkd_nivo_dfo = op_create_entity(\n    entity_id=\"kd_nivolumab_dfo_01\",\n    class_iri=\"qudt:QuantityValue\",\n    graph=\"entity\"\n)\nprint(f\"Created KD Nivolumab-DFO: {kd_nivo_dfo}\")\n\nop_set_literal(\"ex:kd_nivolumab_dfo_01\", \"rdfs:label\", \"KD of Nivolumab-DFO to PD-1\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:kd_nivolumab_dfo_01\", \"qudt:numericValue\", \"3.75\", datatype_iri=\"xsd:double\", graph=\"entity\")\n\nop_set_literal(\"ex:kd_nivolumab_dfo_01\", \"qudt:unit\", \"nM\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:kd_nivolumab_dfo_01\", \"rdfs:comment\",\n               \"Dissociation constant for Nivolumab-DFO binding to human PD-1, measured by SPR\",\n               datatype_iri=None, graph=\"entity\")\n\n# Link to Nivolumab-DFO entity\nop_add_link(\"ex:nivolumab_dfo_01\", \"sio:has-measurement-value\", \"ex:kd_nivolumab_dfo_01\", graph=\"entity\")\n\n# Ground to KD results paragraph\nop_add_link(\"ex:kd_nivolumab_dfo_01\", \"prov:wasDerivedFrom\", \"ex:b_p004_0012\", graph=\"entity\")\n\nprint()\n\n# 3. Activity range measurement (225-341 MBq)\nactivity_range = op_create_entity(\n    entity_id=\"activity_range_01\",\n    class_iri=\"qudt:QuantityValue\",\n    graph=\"entity\"\n)\nprint(f\"Created activity range: {activity_range}\")\n\nop_set_literal(\"ex:activity_range_01\", \"rdfs:label\", \"Activity of 89Zr-Nivolumab\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:activity_range_01\", \"qudt:numericValue\", \"283\", datatype_iri=\"xsd:double\", graph=\"entity\")\n\nop_set_literal(\"ex:activity_range_01\", \"qudt:unit\", \"MBq\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:activity_range_01\", \"rdfs:comment\",\n               \"Activity range 225-341 MBq (mean ~283 MBq)\",\n               datatype_iri=None, graph=\"entity\")\n\nop_add_link(\"ex:zr89_nivolumab_01\", \"sio:has-measurement-value\", \"ex:activity_range_01\", graph=\"entity\")\n\nop_add_link(\"ex:activity_range_01\", \"prov:wasDerivedFrom\", \"ex:b_p004_0014\", graph=\"entity\")\n\nprint()\n\n# 4. Injected dose measurement\ninjected_dose = op_create_entity(\n    entity_id=\"injected_dose_01\",\n    class_iri=\"qudt:QuantityValue\",\n    graph=\"entity\"\n)\nprint(f\"Created injected dose: {injected_dose}\")\n\nop_set_literal(\"ex:injected_dose_01\", \"rdfs:label\", \"Injected dose in NHP\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:injected_dose_01\", \"qudt:numericValue\", \"54.5\", datatype_iri=\"xsd:double\", graph=\"entity\")\n\nop_set_literal(\"ex:injected_dose_01\", \"qudt:unit\", \"MBq\", datatype_iri=None, graph=\"entity\")\n\nop_set_literal(\"ex:injected_dose_01\", \"rdfs:comment\",\n               \"Injected dose 54.5 \u00b1 11.0 MBq in non-human primates\",\n               datatype_iri=None, graph=\"entity\")\n\nop_add_link(\"ex:zr89_nivolumab_01\", \"sio:has-measurement-value\", \"ex:injected_dose_01\", graph=\"entity\")\n\nop_add_link(\"ex:injected_dose_01\", \"prov:wasDerivedFrom\", \"ex:b_p004_0007\", graph=\"entity\")\n\nprint(\"\\n=== BINDING AFFINITY AND ACTIVITY MEASUREMENTS CREATED ===\")", "output": "=== CREATING BINDING AFFINITY MEASUREMENTS ===\n\nCreated KD Nivolumab: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/kd_nivolumab_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}\n\nCreated KD Nivolumab-DFO: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/kd_nivolumab_dfo_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}\n\nCreated activity range: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/activity_range_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}\n\nCreated injected dose: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/injected_dose_01', 'class': 'http://qudt.org/schema/qudt/QuantityValue', 'graph': 'entity'}\n\n=== BINDING AFFINITY AND ACTIVITY MEASUREMENTS CREATED ===\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788533+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 15, "reasoning": "Good progress! I've created comprehensive entities in G_entity for:\n- Chemical entities (Nivolumab, DFO, Zr-89, conjugates)\n- Biological targets (PD-1, PD-L1, PD-L2)\n- Measurements (CAR, yields, purity, specific activity, KD values, doses)\n\nNow I need to:\n1. Create claims in G_claim about the scientific findings:\n   - Spleen uptake reduction with carrier-added studies\n   - Binding affinity preservation after conjugation\n   - Successful PET imaging in NHP\n   - Biodistribution characteristics\n2. Validate the graphs to ensure SHACL conformance\n3. Finalize and submit\n\nLet me create the key claims in the G_claim graph, linking them to the entities and evidence from G_doc.", "code": "# Create scientific claims in G_claim graph\n\nprint(\"=== CREATING SCIENTIFIC CLAIMS ===\\n\")\n\n# 1. Claim about spleen uptake reduction\nspleen_claim = op_create_entity(\n    entity_id=\"claim_spleen_uptake_01\",\n    class_iri=\"sio:Statement\",\n    graph=\"claim\"\n)\nprint(f\"Created spleen uptake claim: {spleen_claim}\")\n\nop_set_literal(\"ex:claim_spleen_uptake_01\", \"rdfs:label\", \n               \"Spleen uptake reduction with carrier-added nivolumab\", \n               datatype_iri=None, graph=\"claim\")\n\nop_set_literal(\"ex:claim_spleen_uptake_01\", \"rdfs:comment\",\n               \"Distribution of radioactivity into the spleen was reduced by 82.5 \u00b1 4.6% (range: -75.2 to -87.0%) by addition of unlabeled nivolumab compared to tracer only studies at all imaging time points\",\n               datatype_iri=None, graph=\"claim\")\n\n# Link to evidence in G_doc\nop_add_link(\"ex:claim_spleen_uptake_01\", \"prov:wasDerivedFrom\", \"ex:b_p005_0013\", graph=\"claim\")\n\n# Link to the tracer entity\nop_add_link(\"ex:claim_spleen_uptake_01\", \"sio:is-about\", \"ex:zr89_nivolumab_01\", graph=\"claim\")\n\nprint()\n\n# 2. Claim about binding affinity preservation\nbinding_claim = op_create_entity(\n    entity_id=\"claim_binding_preservation_01\",\n    class_iri=\"sio:Statement\",\n    graph=\"claim\"\n)\nprint(f\"Created binding preservation claim: {binding_claim}\")\n\nop_set_literal(\"ex:claim_binding_preservation_01\", \"rdfs:label\",\n               \"Binding affinity preserved after DFO conjugation\",\n               datatype_iri=None, graph=\"claim\")\n\nop_set_literal(\"ex:claim_binding_preservation_01\", \"rdfs:comment\",\n               \"KD values for nivolumab (3.10 nM) and nivolumab-DFO (3.75 nM) binding to hPD-1 are similar, indicating that DFO conjugation does not significantly affect binding affinity\",\n               datatype_iri=None, graph=\"claim\")\n\n# Link to evidence\nop_add_link(\"ex:claim_binding_preservation_01\", \"prov:wasDerivedFrom\", \"ex:b_p004_0012\", graph=\"claim\")\n\n# Link to relevant entities\nop_add_link(\"ex:claim_binding_preservation_01\", \"sio:is-about\", \"ex:nivolumab_dfo_01\", graph=\"claim\")\nop_add_link(\"ex:claim_binding_preservation_01\", \"sio:is-about\", \"ex:kd_nivolumab_01\", graph=\"claim\")\nop_add_link(\"ex:claim_binding_preservation_01\", \"sio:is-about\", \"ex:kd_nivolumab_dfo_01\", graph=\"claim\")\n\nprint()\n\n# 3. Claim about successful radiolabeling\nradiolabel_claim = op_create_entity(\n    entity_id=\"claim_radiolabeling_01\",\n    class_iri=\"sio:Statement\",\n    graph=\"claim\"\n)\nprint(f\"Created radiolabeling claim: {radiolabel_claim}\")\n\nop_set_literal(\"ex:claim_radiolabeling_01\", \"rdfs:label\",\n               \"Successful 89Zr radiolabeling of nivolumab-DFO\",\n               datatype_iri=None, graph=\"claim\")\n\nop_set_literal(\"ex:claim_radiolabeling_01\", \"rdfs:comment\",\n               \"89Zr-labeling yielded 225-341 MBq with moderate radiochemical yield of 53 \u00b1 8% (non-decay-corrected) and specific activity of 352 \u00b1 87 MBq/mg\",\n               datatype_iri=None, graph=\"claim\")\n\n# Link to evidence\nop_add_link(\"ex:claim_radiolabeling_01\", \"prov:wasDerivedFrom\", \"ex:b_p004_0014\", graph=\"claim\")\nop_add_link(\"ex:claim_radiolabeling_01\", \"prov:wasDerivedFrom\", \"ex:b_p005_0010\", graph=\"claim\")\n\n# Link to relevant entities\nop_add_link(\"ex:claim_radiolabeling_01\", \"sio:is-about\", \"ex:zr89_nivolumab_01\", graph=\"claim\")\nop_add_link(\"ex:claim_radiolabeling_01\", \"sio:is-about\", \"ex:radiochemical_yield_01\", graph=\"claim\")\nop_add_link(\"ex:claim_radiolabeling_01\", \"sio:is-about\", \"ex:specific_activity_01\", graph=\"claim\")\n\nprint()\n\n# 4. Claim about conjugation efficiency\nconjugation_claim = op_create_entity(\n    entity_id=\"claim_conjugation_01\",\n    class_iri=\"sio:Statement\",\n    graph=\"claim\"\n)\nprint(f\"Created conjugation claim: {conjugation_claim}\")\n\nop_set_literal(\"ex:claim_conjugation_01\", \"rdfs:label\",\n               \"Efficient DFO conjugation to nivolumab\",\n               datatype_iri=None, graph=\"claim\")\n\nop_set_literal(\"ex:claim_conjugation_01\", \"rdfs:comment\",\n               \"Nivolumab-DFO was isolated with 88% yield (8.", "output": "=== CREATING SCIENTIFIC CLAIMS ===\n\nCreated spleen uptake claim: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/claim_spleen_uptake_01', 'class': 'http://semanticscience.org/resource/Statement', 'graph': 'claim'}\n\nCreated binding preservation claim: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/claim_binding_preservation_01', 'class': 'http://semanticscience.org/resource/Statement', 'graph': 'claim'}\n\nCreated radiolabeling claim: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/claim_radiolabeling_01', 'class': 'http://semanticscience.org/resource/Statement', 'graph': 'claim'}\n\nCreated conjugation claim: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/claim_conjugation_01', 'class': 'http://semanticscience.org/resource/Statement', 'graph': 'claim'}\n\nCreated PET imaging claim: {'operator': 'op_create_entity', 'node': 'http://la3d.local/kag/doc/claim_pet_imaging_01', 'class': 'http://semanticscience.org/resource/Statement', 'graph': 'claim'}\n\n=== SCIENTIFIC CLAIMS CREATED ===\n\n=== VALIDATING GRAPHS ===\n\nValidation result: {\n  \"conforms\": false,\n  \"layers\": {\n    \"entity\": {\n      \"conforms\": false,\n      \"total_violations\": 2,\n      \"violations\": [\n        {\n          \"node\": \"http://la3d.local/kag/doc/car_measurement_01\",\n          \"message\": \"MeasuredValue must have exactly one qudt:unit. Fix: op_set_link(mv_iri, 'qudt:unit', 'unit:ANGSTROM').\"\n        },\n        {\n          \"node\": \"http://la3d.local/kag/doc/car_measurement_01\",\n          \"message\": \"QuantityValue must have exactly one qudt:unit. Fix: op_set_link(qv_iri, 'qudt:unit', 'unit:DEG_C').\"\n        }\n      ]\n    },\n    \"claim\": {\n      \"conforms\": true,\n      \"total_violations\": 0\n    },\n    \"cross_graph\": {\n      \"conforms\": true,\n      \"ungrounded\": [],\n      \"total_ungrounded\": 0\n    }\n  }\n}\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788583+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 16, "reasoning": "I see validation errors! The CAR measurement entity needs a proper qudt:unit link (not a literal). The SHACL validator is telling me that:\n1. CAR measurement (ex:car_measurement_01) is missing a qudt:unit link to a unit IRI\n2. It needs to use op_set_link instead of op_set_literal for the unit\n\nCAR (chelator-to-antibody ratio) is a dimensionless ratio, so I should use a dimensionless unit from QUDT. Let me fix this and also check if any other measurements need unit fixes.\n\nLooking at my measurements:\n- CAR: dimensionless ratio - needs unit:UNITLESS or similar\n- Conjugation yield: percent - needs proper unit IRI\n- Purity: percent - needs proper unit IRI  \n- Radiochemical yield: percent - needs proper unit IRI\n- Specific activity: MBq/mg - needs proper unit IRI\n- KD values: nM - needs proper unit IRI\n- Activity: MBq - needs proper unit IRI\n- Injected dose: MBq - needs proper unit IRI\n\nI need to fix all of these by using op_set_link with proper QUDT unit IRIs instead of literal strings.", "code": "# Fix the unit issues - need to use op_set_link with proper QUDT unit IRIs\n\nprint(\"=== FIXING UNIT LINKS FOR MEASUREMENTS ===\\n\")\n\n# 1. Fix CAR measurement - dimensionless ratio\nop_set_link(\"ex:car_measurement_01\", \"qudt:unit\", \"unit:UNITLESS\", graph=\"entity\")\nprint(\"Fixed CAR unit\")\n\n# 2. Fix conjugation yield - percent\nop_set_link(\"ex:conjugation_yield_01\", \"qudt:unit\", \"unit:PERCENT\", graph=\"entity\")\nprint(\"Fixed conjugation yield unit\")\n\n# 3. Fix purity - percent\nop_set_link(\"ex:purity_measurement_01\", \"qudt:unit\", \"unit:PERCENT\", graph=\"entity\")\nprint(\"Fixed purity unit\")\n\n# 4. Fix radiochemical yield - percent\nop_set_link(\"ex:radiochemical_yield_01\", \"qudt:unit\", \"unit:PERCENT\", graph=\"entity\")\nprint(\"Fixed radiochemical yield unit\")\n\n# 5. Fix specific activity - MBq/mg (need to find appropriate unit or use custom)\n# MBq/mg is activity per mass - use MegaBQ-PER-GM\nop_set_link(\"ex:specific_activity_01\", \"qudt:unit\", \"unit:MegaBQ-PER-GM\", graph=\"entity\")\nprint(\"Fixed specific activity unit\")\n\n# 6. Fix KD Nivolumab - nM (nanomolar)\nop_set_link(\"ex:kd_nivolumab_01\", \"qudt:unit\", \"unit:NanoMOL-PER-L\", graph=\"entity\")\nprint(\"Fixed KD Nivolumab unit\")\n\n# 7. Fix KD Nivolumab-DFO - nM\nop_set_link(\"ex:kd_nivolumab_dfo_01\", \"qudt:unit\", \"unit:NanoMOL-PER-L\", graph=\"entity\")\nprint(\"Fixed KD Nivolumab-DFO unit\")\n\n# 8. Fix activity range - MBq\nop_set_link(\"ex:activity_range_01\", \"qudt:unit\", \"unit:MegaBQ\", graph=\"entity\")\nprint(\"Fixed activity range unit\")\n\n# 9. Fix injected dose - MBq\nop_set_link(\"ex:injected_dose_01\", \"qudt:unit\", \"unit:MegaBQ\", graph=\"entity\")\nprint(\"Fixed injected dose unit\")\n\nprint(\"\\n=== ALL UNITS FIXED ===\\n\")\n\n# Validate again\nprint(\"=== RE-VALIDATING GRAPHS ===\\n\")\nvalidation_result = validate_graph(\"all\")\nprint(f\"Validation result: {json.dumps(validation_result, indent=2)}\")", "output": "=== FIXING UNIT LINKS FOR MEASUREMENTS ===\n\nFixed CAR unit\nFixed conjugation yield unit\nFixed purity unit\nFixed radiochemical yield unit\nFixed specific activity unit\nFixed KD Nivolumab unit\nFixed KD Nivolumab-DFO unit\nFixed activity range unit\nFixed injected dose unit\n\n=== ALL UNITS FIXED ===\n\n=== RE-VALIDATING GRAPHS ===\n\nValidation result: {\n  \"conforms\": true,\n  \"layers\": {\n    \"entity\": {\n      \"conforms\": true,\n      \"total_violations\": 0\n    },\n    \"claim\": {\n      \"conforms\": true,\n      \"total_violations\": 0\n    },\n    \"cross_graph\": {\n      \"conforms\": true,\n      \"ungrounded\": [],\n      \"total_ungrounded\": 0\n    }\n  }\n}\n", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.788622+00:00", "event_type": "iteration", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "iteration": 17, "reasoning": "Excellent! All graphs now validate successfully with SHACL conformance. I have successfully:\n\n1. Created comprehensive chemical entities in G_entity:\n   - Nivolumab (anti-PD-1 antibody)\n   - DFO chelator (p-SCN-Bn-DFO)\n   - Zr-89 radioisotope\n   - Nivolumab-DFO conjugate\n   - 89Zr-Nivolumab final tracer\n\n2. Created biological target entities:\n   - PD-1, PD-L1, PD-L2 proteins\n\n3. Created comprehensive measurements with proper QUDT units:\n   - CAR: 1.14 (unitless)\n   - Conjugation yield: 88%\n   - Purity: >95%\n   - Radiochemical yield: 53 \u00b1 8%\n   - Specific activity: 352 \u00b1 87 MBq/mg\n   - KD values: 3.10 nM (Nivolumab), 3.75 nM (Nivolumab-DFO)\n   - Activity: 225-341 MBq\n   - Injected dose: 54.5 \u00b1 11.0 MBq\n\n4. Created scientific claims in G_claim:\n   - Spleen uptake reduction with carrier-added studies\n   - Binding affinity preservation after conjugation\n   - Successful radiolabeling\n   - Efficient conjugation\n   - PET imaging feasibility in NHP\n\n5. All entities are properly grounded to G_doc sources via prov:wasDerivedFrom links\n\n6. All graphs validate successfully (conforms: true)\n\nNow I need to finalize the extraction by calling finalize_graph() with a summary, which will gate the final SUBMIT.", "code": "# Prepare summary of extraction\nsummary = \"\"\"\nExtracted key entities, measurements, and claims from paper on 89Zr-Nivolumab PET imaging:\n\nCHEMICAL ENTITIES (5):\n- Nivolumab: Anti-PD-1 monoclonal antibody\n- p-SCN-Bn-DFO: Bifunctional chelator\n- Zirconium-89: PET radioisotope\n- Nivolumab-DFO: Conjugate (CAR 1.14, 88% yield, >95% purity)\n- 89Zr-Nivolumab: Final PET tracer\n\nBIOLOGICAL TARGETS (3):\n- PD-1, PD-L1, PD-L2 proteins\n\nMEASUREMENTS (9):\n- CAR: 1.14\n- Conjugation yield: 88%\n- Purity: >95%\n- Radiochemical yield: 53 \u00b1 8%\n- Specific activity: 352 \u00b1 87 MBq/mg\n- KD (Nivolumab): 3.10 nM\n- KD (Nivolumab-DFO): 3.75 nM\n- Activity range: 225-341 MBq\n- Injected dose: 54.5 \u00b1 11.0 MBq\n\nSCIENTIFIC CLAIMS (5):\n1. Spleen uptake reduced 82.5 \u00b1 4.6% with carrier-added nivolumab\n2. Binding affinity preserved after DFO conjugation\n3. Successful 89Zr radiolabeling achieved\n4. Efficient DFO conjugation to nivolumab\n5. 89Zr-nivolumab enables PET imaging in NHP\n\nAll entities grounded to document sources. All graphs SHACL-conformant.\n\"\"\"\n\n# Finalize the graph\nfinalize_result = finalize_graph(summary)\nprint(\"=== FINALIZATION RESULT ===\")\nprint(json.dumps(finalize_result, indent=2))\n\n# If ready, submit\nif finalize_result.get('status') == 'READY':\n    print(\"\\n=== ALL GRAPHS VALIDATED - READY TO SUBMIT ===\")\n    SUBMIT(summary)\nelse:\n    print(\"\\n=== NOT READY - CHECK VALIDATION ISSUES ===\")\n    print(finalize_result)", "output": "FINAL: {'answer': '\\nExtracted key entities, measurements, and claims from paper on 89Zr-Nivolumab PET imaging:\\n\\nCHEMICAL ENTITIES (5):\\n- Nivolumab: Anti-PD-1 monoclonal antibody\\n- p-SCN-Bn-DFO: Bifunctional chelator\\n- Zirconium-89: PET radioisotope\\n- Nivolumab-DFO: Conjugate (CAR 1.14, 88% yield, >95% purity)\\n- 89Zr-Nivolumab: Final PET tracer\\n\\nBIOLOGICAL TARGETS (3):\\n- PD-1, PD-L1, PD-L2 proteins\\n\\nMEASUREMENTS (9):\\n- CAR: 1.14\\n- Conjugation yield: 88%\\n- Purity: >95%\\n- Radiochemical yield: 53 \u00b1 8%\\n- Specific activity: 352 \u00b1 87 MBq/mg\\n- KD (Nivolumab): 3.10 nM\\n- KD (Nivolumab-DFO): 3.75 nM\\n- Activity range: 225-341 MBq\\n- Injected dose: 54.5 \u00b1 11.0 MBq\\n\\nSCIENTIFIC CLAIMS (5):\\n1. Spleen uptake reduced 82.5 \u00b1 4.6% with carrier-added nivolumab\\n2. Binding affinity preserved after DFO conjugation\\n3. Successful 89Zr radiolabeling achieved\\n4. Efficient DFO conjugation to nivolumab\\n5. 89Zr-nivolumab enables PET imaging in NHP\\n\\nAll entities grounded to document sources. All graphs SHACL-conformant.\\n'}", "has_error": false, "error_type": null}}
{"timestamp": "2026-02-11T13:22:13.833715+00:00", "event_type": "run_complete", "data": {"run_id": "kag_entity_pet_20260211T131729Z", "conforms": true, "entity_triples": 102, "claim_triples": 33, "iterations": 17, "total_cost": 0.91863, "sandbox_crashes": 0, "tool_binding_errors": 0}}
